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ABSTRACT OF THE DISSERTATION
AN INVESTIGATION INTO THE ADDUCT FORMING POTENTIAL OF DRUGS
OF ABUSE WITH PEPTIDES AND PROTEINS
by
Richard Allen Gilliland
Florida International University, 2018
Miami, Florida
Professor Anthony DeCaprio, Major Professor
Hemoglobin and serum albumin, two prevalent proteins in human blood,
contain unbound cysteine thiol moieties, creating a nucleophilic site with the
potential for covalent modification by reactive chemical species. These covalent
modifications, called “adducts”, are stable entities that accumulate during acute
and chronic exposure and remain covalently bound for the life-span of the
protein. Despite their current use as exposure markers for a variety of
compounds, the use of adducts in assessing exposure to drugs of abuse has not
yet been explored. The goal of this work was to examine the in vitro adduct
forming capability of selected drugs of abuse with hemoglobin to provide
additional proof of principle for the development of a real-world detection and
monitoring analysis method. This goal was accomplished by first analyzing the
binding capabilities of the drugs of interest with glutathione, a smaller tripeptide.
Use of protein adducts as biomarkers of drug exposure may allow for an
increased window of detection, from several days to several months, as
compared to current blood analysis methods. In total, there were 16 drugs
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analyzed in the research, and they covered a wide range of abused drugs,
including cocaine, methamphetamine, and Δ9-THC.
Results from the glutathione trials showed that 10 of the 16 the drugs of
interest were able to form covalent adducts with the free thiol moiety, with four
drugs forming more than one novel adduct. The MS results for hemoglobin
showed 11 adducts formed for five of the drugs under investigation. Additional
MS/MS confirmatory data was obtained for two of those 11 adducts. I
successfully identifyied adducts formed between drugs of abuse and glutathione
and hemoglobin, which have the potential to be used as long-term biomarkers of
exposure.
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1. INTRODUCTION
Xenobiotic drugs have been used by humans for millennia and continue to
be a problem today. The current detection methods for drugs of abuse involve
the identification of a biomarker of exposure in a bodily matrix; typically blood,
urine, or hair. The biomarkers used for drug analysis are either the parent drug or
a common metabolite which can be analyzed. For blood and urine analysis,
drugs and metabolites are generally only observable for several days, with
lipophilic drugs existing in the system for no more than two weeks. For hair
analysis, the biomarkers may be detected several months, or possibly years,
after ingestion, depending upon the length and rate of growth of the individual’s
hair. Current hair analysis has many obstacles however, including a lack of
consensus regarding incorporation of biomarkers into hair, wide variation of
extraction methods, and the limited ability to distinguish between internal drug
incorporation and external surface exposure.
A type of biomarker that has not yet been widely applied to the analysis of
drugs of abuse involves measurement of covalent protein modifications (i.e.,
protein “adducts”). When xenobiotics are metabolized, some of the products
created may be reactive metabolic species capable of forming covalent bonds
with certain amino acid residues in proteins. Such protein adducts are, in
general, much longer lived in the body than the parent compound or its
metabolites.
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The current research explored the capabilities of a wide variety of drugs of
abuse to form covalent protein adducts with cysteine residues present in
hemoglobin, a prominent and essential blood protein. This exploration was
accomplished by first analyzing the adduct forming capabilities of the drugs with
glutathione, a small tripeptide containing a reactive cysteine moiety, in an in vitro
metabolic assay system. Following the characterization of the glutathione
adducts formed, hemoglobin adducts were created and analyzed using the same
in vitro assay, providing insight into the potential covalent adduct forming
capabilities of the drugs of interest and the properties and localization of the
generated protein modifications. My research establishes the potential for drugprotein adducts to be used as biomarkers of exposure and creates the necessary
foundation for future work to continue with these compounds toward the goal of a
validated and widely applicable alternative to hair analysis for retrospective
abused drug detection.
2. LITERATURE REVIEW
2.1 Drugs of Abuse
In 2014, there were an estimated 44 million drug users in the United
States, with the numbers continually increasing.1 Despite their prevalence and
popularity in today’s society, many plant-based produced drugs of abuse like
heroin and cocaine have long and elaborate histories. Opium, from which heroin
is derived, can be traced back over 1000 years to the ancient Greeks, whereas
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cocaine was used for religious and ceremonial reasons by the ancient
civilizations in the Americas.2,3 Over the years, the number of abused drugs has
continued to increase and now includes many synthetic compounds in addition to
the naturally derived ones.4 In the United States, the Drug Enforcement
Administration (DEA) categorizes drugs into five schedules according to a drug’s
medical uses and dependency potential.5 Any drug that does not fit into one of
the DEA’s five schedules is categorized as an over the counter (OTC) medication
or non-scheduled prescription medication. Table 1 lists all of the current DEA
schedule classifications and the properties of the drugs found in each one.

Drugs, substances, or chemicals with no currently accepted
Schedule I medical use by the federal government and a high potential for
abuse
Drugs, substances, or chemicals with high potential for abuse,
Schedule II
but which do have an accepted medical use
Drugs, substances, or chemicals with moderate to low potential
Schedule III
for abuse and dependence
Drugs, substances, or chemicals with low potential for abuse
Schedule IV
and dependence
Drugs, substances, or chemicals with lower potential for abuse
Schedule V than Schedule IV and preparations containing limited quantities
of certain narcotics
Table 1. Drug schedules as determined by the U.S. DEA.

Depending upon the source consulted, there are generally anywhere from
four to eight recognized classes of abused drugs upon pharmacological effect.6-9
These classes include depressants, stimulants, hallucinogens, opioids,
antipsychotics, cannabis, and novel psychoactive substances (NPS).10 These
categories are a result of categorizing the drugs depending primarily upon the
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effect on the central nervous system (CNS) of the user and the source of the
compound itself. There will often be some overlap regarding the CNS effects of
these classes. For example, opioids have a similar effect to most depressants
yet are categorized separately.
The drugs of interest in this study included α-pyrrolidinopentiophenone,
acetaminophen, alprazolam, buprenorphine, clozapine, cocaine, diazepam,
methadone, methamphetamine, methylenedioxymethamphetamine,
methylenedioxypyrovalerone, methylone, morphine, naltrexone, oxycodone, and
Δ9-tetrahydrocannabinol. Table 2 shows the schedule and drug class for each of
these compounds along with other identifying information.
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Drug Name

Abbreviation

Formula

Schedule

Class

α-Pyrrolidinopentiophenone

α-PVP

C15H21NO

I

Acetaminophen

APAP

C8H9NO2

OTC

NPS/
Stimulant
Analgesic

Alprazolam

ALP

C17H13ClN4

IV

Depressant

Buprenorphine

BUP

C29H41NO4

III

Opioid

Clozapine

CLZ

C18H19ClN4

Rx

Antipsychotic

Cocaine

COC

C17H21NO4

II

Stimulant

Diazepam

DZP

C16H13ClN2O

IV

Depressant

Methadone

META

C21H27NO

II

Opioid

Methamphetamine

METH

C10H15N

II

Methylenedioxymethamphetamine

MDMA

C11H15NO2

I

Methylenedioxypyrovalerone

MDPV

C16H21NO3

I

Methylone

METY

C11H13NO3

I

Morphine

MOR

C17H19NO

II

Stimulant
Stimulant/
Hallucinogen
NPS/
Stimulant
NPS/
Stimulant
Opioid

Naltrexone

NAL

C20H23NO4

Rx

Opioid

Oxycodone

OXY

C18H21NO4

II

Opioid

Δ9-Tetrahydrocannabinol

THC

C21H30O2

I

Cannabinoid

Table 2. The drugs of interest selected for this study in addition to the abbreviations used
for each. Table 2 also lists the formula, US DEA schedule, and general class of each drug
of interest.

2.2 Drug Metabolism
The lifespan of any xenobiotic within the body can be characterized by its
absorption, distribution, metabolism, and excretion (ADME) parameters.
Absorption describes the process by which a compound is taken up by the body,
and the process is affected by the route of administration. Distribution refers to
the overall pharmacokinetics of an absorbed chemical species, specifically the
transfer of a chemical from where it was absorbed to where it may have an
effect. Metabolism refers to the breakdown of a precursor chemical into its
metabolites. These metabolites may be either pharmacologically active or
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inactive. Excretion is the process of removing chemicals and their metabolites
from the body; failure to efficiently removed compounds may lead to
accumulation over time. As previously stated, the metabolism of a chemical
species may result in pharmacologically active metabolites capable of producing
unforeseen and toxic results. As a result of factors such as nutritional state,
gender, and dosage, no two individuals will metabolize the same drug in the
same way11, although it is possible to determine general metabolic trends for
drugs and classes of drugs.
2.2.1 Phase I Metabolism
Metabolic processes may be divided into two categories: Phase I and
Phase II metabolism. Phase I metabolic processes generally form metabolites
which are more polar than the parent xenobiotic and are typically a means of
detoxification (or, in some cases, toxification) and preparation for excretion.
Phase I metabolism refers to a number of reactions that a xenobiotic may
undergo where a relatively small chemical modification, such as a hydroxylation
or an epoxidation, occurs which may slightly increase hydrophilicity. While
Phase I metabolic reactions occur in a variety of organs and tissues in the body,
these reactions are predominantly carried out by cytochrome P450 (CYP)
enzymes in the liver, with some estimates stating this organ accounts for ~90%
of all metabolic activity.12
The CYP enzymes are a type of enzyme known as hemoproteins, thus
named due to a heme group located in the active site of the protein. For more
information regarding the heme complex, see 2.4.4. The heme group is
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responsible for the CYP family’s activity as Phase I metabolic enzymes. CYP
enzymes are capable of catalyzing otherwise difficult chemical oxidations,
including hydroxylation of unfunctionalized alkyl chains13, which is accomplished
via cycling the oxidation state of the iron within the heme group, as can be seen
in Figure 1. This cycling process is proposed many times in the extant literature
on CYP enzymes14-16. In step (a), the ferric iron of the CYP enzyme is hexacoordinated and in the low-spin state when the substrate to be oxidized (RH) is
introduced, leading to the loss of a water molecule and the formation of a highspin penta-coordinated complex (b). Following the reduction of the iron to ferrous
FeII (c), the iron can react with an oxygen molecule to form an oxygenated
species (d), which is then further reduced to give a peroxy-complex (e). After the
addition of two protons, heterolytic cleavage results in an oxo-ferryl oxenoid
intermediate (f). A hydrogen atom is then abstracted from the substrate in
solution, producing the reduced hydroxy ferric species and substrate radical (g).
This production leads to a coordinated oxidized substrate species which then
releases the oxidized substrate and produces the initial low-spin ferric compound
(a). The CYP enzymes are not only responsible for hydroxylations, as they are
capable of performing multiple other oxidative biotranformations on xenobiotics,
as seen in Table 3.
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Figure 1. The process of heme cycling by a CYP enzyme to produce an oxidized substrate.

Chemical
group
Alkane

Reactions

Alkene
Alkyne

Hydroxylation,
dehydrogenation
Epoxidation
Oxidation to carboxylic acid

Arene
Aniline

Hydroxylation, epoxidation
N-hydroxylation

Ester
Ether

Oxidative cleavage
O-dealkylation

Table 3. Some of the chemical groups which may be metabolized by CYP enzymes and the
reactions possible with each.
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Another means of oxidation in a molecule is the process of an “NIH” shift,
named for the National Institute of Health, where it was first described.17 There
are several proposed mechanisms by which an NIH shift may occur, however,
the prevailing theory, which has been experimentally corroborated, involves
formation of an unstable epoxide which then undergoes a hydride shift. 17,18 While
the process is typically followed by a rearomatization step, in situations where
GSH or a similar nucleophile is present, rearomatization is not always seen 19.19
2.2.2 Phase II Metabolism
Phase II metabolism refers to reactions where the addition of a large polar
moiety substantially increases hydrophilicity, such as conjugation to glucuronic
acid. The increase in hydrophilicity results in more facile excretion of the
compound from the body in the urine. In contrast, conjugation with glutathione,
particularly in the liver, can result in excretion of Phase II metabolites via bile and
feces. There are several metabolic processes which may result from Phase II
metabolism, as can be seen in Table 4. Table 4 also shows some of the various
enzymes and cofactors required for these reactions to take place.
Process
Methylation

Enzyme
methyltransferase

Sulfation

Sulfotransferase

Acetylation
Glucuronidation
Glutathione
conjugation

N-acetyltransferase
UDP-glucuronosyltransferase
Glutathione-s-transferase

Co-Factor
S-andeosyl-Lmethionine (SAM)
3’-phosphoadenosine5’-phosphosulfate
(PAPS)
Acetyl coenzyme A
UDP-glucuronic acid
Glutathione

Table 4. Phase II metabolic processes and the respective enzymes and co-factors required
for each
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2.3 Biomarkers of Exposure
Biomarkers of exposure are entities which are indicative of exposure to a
chemical or class of chemicals. In terms of drugs of abuse, the most commonly
analyzed biomarkers to determine exposure are either the parent drug or a stable
metabolite. Since metabolism primarily occurs in the liver and metabolic
processes are designed to facilitate excretion, biomarkers are selected on the
basis of the specific matrix collected for analysis. Although there are many
different matrices that may be utilized for the analysis of drugs, the three primary
ones are blood, urine, and hair, with each offering benefits and drawbacks.

20-22

2.3.1 Blood and Urine as a Matrix
Blood and urine are both well-characterized matrices with extensive
protocols for exposure biomarker analysis established in the literature. 22-25 While
it may be possible to detect precursor drugs and their metabolites in both blood
and urine, precursor drugs are typically used as biomarkers in blood and
metabolites used as biomarkers in urine. Since blood and urine are both aqueous
matrices, the utilization of liquid chromatographic (LC) separation in analysis
requires fewer steps, as there are typically few solubility issues with the desired
biomarker analytes. While a plethora of information already in the literature
addresses many potential problems with the analysis of drugs in both blood and
urine, they each still have drawbacks. Both blood and urine are collected via
invasive means, leading to privacy issues in collection.26 Blood and urine also
have limited windows of detection for currently utilized biomarkers.

27

Depending

upon the properties of the drug, the window of detection may be less than a
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day28, with some more lipophilic drug biomarkers being detectable for no more
than about a few weeks. 29 A comparison of several drugs of abuse and their
relative windows of detection in both blood and urine can be found in Table 5.28

Parent Drug

Analyte

Detection Time in
Blood (h)

Methamphetamine

Methamphetamine

48

Detection
Time in Urine
(h)
87 ± 51

MDMA
Cannabis
Cannabis
Heroin

MDMA
THC
THCCOOH
Morphine

24
5
36
20

48
N/A
87
11-54

Table 5. A summary of the retention times in blood and urine for methamphetamine,
MDMA, cannabis, and heroin, as reported in hours.

2.3.2 Hair as a Matrix
The use of hair as a matrix is another common approach to drug analysis
and exposure assessment. The literature regarding hair analysis is not as
encompassing as it is for either blood or urine, but there are still many protocols
published for the analysis of drugs in hair. Hair is collected through less invasive
means than both blood and urine, and the window of detection for hair analysis
can be significantly longer, with the potential for drugs to persist in hair for
months or years. 21 A comparison of detection windows for each matrix can be
found in Figure 2. In addition to the extended window of detection, the use of hair
as a matrix also allows for segmental analysis. Segmental analysis consists of
the partitioning of the hairs collected and analyzing each partition separately,
allowing for a timeline of previous drug exposure to be compiled for an individual.
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30

The biomarkers typically examined in hair analysis are both parent drugs and

their metabolites.31 Unfortunately, there is no single incorporation mechanism for
drugs into the hair, as direct incorporation into hair from blood, adsorption from
sweat, and adsorption from smoke or powders are all potential routes of
incorporation.32 Additionally, in the existing protocols, there is no way to
distinguish biomarkers present from ingestion of a compound from biomarkers
present from surface contamination of the hair without first utilizing extensive
washing procedures to remove external contaminants.33 These washing
procedures are not guaranteed to remove all of the external contaminants, as
some drugs may bind more strongly to hair than others.34 In addition, washing
procedures may also result in loss of drug that was incorporated from the blood.
Lastly, since hair is a solid matrix, there are several steps required prior to
analysis to extract and clean up the sample to analyzed.30

Figure 2. The window of detection for cocaine and its metabolites in blood, urine, and hair
set to a logarithmic scale.35
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2.4 Use of Protein Adducts as Exposure Biomarkers
The drawbacks in the use of blood, urine, or hair as testing matrices for
drugs and other xenobiotics has led to interest in the use of alternative matrices
or biomarkers to bypass these difficulties. One such example is the use of protein
adducts as biomarkers of exposure. Protein adducts are formed as the result of a
covalent modification to a protein by a directly reactive xenobiotic or a metabolite
formed by the xenobiotic. Covalent protein adduction is common occurrence in
the body, with many modifications being of relatively low molecular weight, for
example reactive oxygen species (ROS)36,37 and reactive nitrogen species
(RNS)38,39. Larger modifications are possible however, with examples such as
glutathionylation and lipid peroxidation product adduction.40 While some protein
modifications may be unstable in certain protein microenvironments, as is the
case with compounds such as 4-hydroxy-2-nonenal 41, in general, covalent
protein adduct formation is an irreversible phenomenon

42.

Unlike DNA,

essentially no cellular repair mechanisms exist for covalent protein
modifications42, meaning that most protein adducts are typically extant for the
remaining life of the protein.
Recognition of the adduction of reactive electrophiles created in vivo to
proteins first emerged in the 1930s and 1940s, first with Fieser’s work regarding
the hepatotoxicity of various hydrocarbons43 and then with work done by Miller
and Miller regarding the binding of aminoazo dyes to the cellular constituents of
the livers of rats fed p-dimethylaminoazobenzene, a known hepatic carcinogen 44.
These studies laid the groundwork for what became known as the “covalent
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binding theory”, which proposed that certain chemicals were able to covalently
bind to macromolecules in the body causing toxicity.45 This progression
continued when Brodie, et al. were able to show that bromobenzene is
metabolically activated and covalently binds to proteins in the liver, resulting in
liver necrosis.46 Since then, the concept of xenobiotic induced protein adduction
has continued to expand and is now a major area of interest for new drug
development where such adducts may mediate drug toxicity or participate in the
therapeutic mechanism of certain drugs.45
The use of protein adducts as exposure biomarkers is also not a new
concept. Since the idea of utilizing them for the biomonitoring of various
compounds was first suggested in the 1970s 46,47, research regarding protein
adducts has continued to expand. In 1986, Skipper et al. looked at new analytical
methods to measure protein adducts with 4-aminobiphenyl48, an arylamine
capable of causing bladder cancer in human and dogs.49 Research published in
1989 by Tornqvist et al. analyzed protein adducts formed upon exposure to four
types of gasoline and diesel exhaust.50 In 1993, Christakopoulos et al.
characterized styrene-protein adducts present in authentic collected blood
samples from factory workers exposed to styrene.51
2.4.1 Protein Adduction by Drugs of Abuse
With few exceptions, there are only limited data available regarding the
potential for important drugs of abuse to form covalent adducts with blood or
tissue proteins. One of the major exceptions is ethanol, where its ability to
interact with proteins has been widely studied. Ethanol’s major metabolite,
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acetaldehyde, is known to form adducts with proteins. The reaction between
acetaldehyde and serum albumin was first characterized in 198252, and the
reaction with hemoglobin was first characterized in 198553. Acetaldehyde’s
protein interactions are generally the result of the formation of an unstable Schiff
base, which then is able to interact with nucleophilic amino acids of proteins. 54
These bases may form stable or unstable adducts, and the stable adducts may
be useful as a means of retrospective detection of exposure. 55,56
Some data are also available for protein adduction by the licit drug
morphine, which is both itself abused and that is a major metabolite of the illicit
drug heroin. A major reactive metabolite of morphine, morphinone, has been
shown, in both in vitro and in vivo studies, to covalently bind to free thiols of
proteins and peptides found in the body.56-59 In vitro studies by Correia, et al.
suggested that formation of a more reactive and unstable reactive species is the
preferred biological transformation of morphine, as the glutathione-morphine
adduct formed by this reactive intermediate was observed at levels two-fold
greater than those of normorphine.60 Previous work Schneider and DeCaprio
also demonstrated the ability of morphine metabolites to form adducts with Nacetylcysteine, glutathione, and a synthetic hexapeptide.56
Another example of an illicit drug which has shown the capability of
binding to protein is cocaine.61 The major site of metabolic activity for cocaine is
reported to be the tropane nitrogen, with numerous oxidative products capable of
being formed at this site.62 Cocaine adducts formed with liver proteins have been
observed in several studies, with further studies into potential hepatotoxic stress
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caused by these adducts.63,64 In 2002, Deng, et al. reported high levels of
covalent binding between metabolically activated cocaine and blood proteins. 65
Additional work by Schneider and DeCaprio investigated the binding of cocaine
to glutathione, a synthetic hexapeptide, and N-acetylated variants of the amino
acids lysine (Lys), cysteine (Cys), and histidine (His).61 Schneider and DeCaprio
also posited that epoxidation of the phenyl ring of cocaine is the first step in the
formation of cocaine adducts, suggesting that the phenyl ring is the site of
adduction.61 This reaction scheme contrasts with what was reported in the 1980s
and 1990s that the tropane nitrogen was the likely site of adduction.66,67
2.4.2 Hard-Soft Acid-Base Theory
The formation of covalent adducts from the reaction of electrophilic
xenobiotics with cellular nucleophiles, including proteins, can be generally
modeled by the “Hard and Soft Acids and Bases” (HSAB) Theory. The HSAB
Theory states that nucleophiles and electrophiles can be categorized on a
spectrum from hard to soft, depending on polarizability. Polarizability is a
characteristic describing electron density for atoms or molecules, and it applies to
the valence electrons in an atomic or molecular electron cloud.68 If the valence
electrons in the cloud are occupying a large volume of space, they will be more
susceptible to outside influence and thus be more polarizable than valence
electrons which are closer to the nucleus and relatively less mobile. These
electrons are considered more polarizing.69 Using this nomenclature, “hard”
refers to a nucleophile or electrophile that is relatively small and highly polarizing.
Alternatively, “soft” refers to a nucleophile or electrophile that is relatively large
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and highly polarizable. According to HSAB Theory, hard electrophiles will tend to
react with hard nucleophiles and vice versa for soft electrophiles and
nucleophiles.
A species’ hardness or softness cannot be directly measured, but instead
can be calculated via its relation to other properties of the compound. The energy
levels of the outermost or frontier molecular orbitals (FMOs) are the most
important component in determining a compounds “hardness”.61 A species’
hardness (η) is equal to the energy of the Lowest Unoccupied Molecular Orbital
(LUMO) minus the energy of the Highest Occupied Molecular Orbital (HOMO)
divided by 2 (Equation 1). A species’ softness (σ) is then defined as the inverse
of the hardness (Equation 2).
𝐸𝐿𝑈𝑀𝑂 −𝐸𝐻𝑂𝑀𝑂

(1)

𝜂=

(2)

𝜎=𝜂

2
1

When dealing with electrophilic species, it is generally the case that a higher
softness results in more facile formation of an adduct with a soft nucleophile. 68
The electrophilic index (ω) is a parameter that combines softness and electric
potential (μ), or the propensity for a compound to undergo a chemical change
(Equations 3 and 4).
𝐸𝐿𝑈𝑀𝑂 +𝐸𝐻𝑂𝑀𝑂

(3)

𝜇=

(4)

𝜔 = 2𝜂

2
𝜇2

The equations presented thus far only apply to an individual species and do not
provide insight into bond forming capabilities between two compounds. For this,
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the nucleophilic index (ω-) can be calculated to predict the likelihood that an
adduct will form between nucleophile A and electrophile B (Equation 5). 70
(5)

𝜔− =

𝜂𝐴 (𝜇𝐴 −𝜇𝐵 )2
2(𝜂𝐴 +𝜂𝐵 )2

When dealing with biological species, heteroatoms such as sulfur, oxygen,
and nitrogen are the most prominent nucleophilic sites.71 Specifically when
dealing with proteins, the sulfurs from amino acid thiol residues react as relatively
soft nucleophiles.72 The softness of the thiol moiety increases as it is converted
to a thiolate (SH  S-) ion, and the thiolate ion is one of the most reactive
biological nucleophiles.68 The base pKa of cysteine is ~8.3, meaning that at
physiological pH (~7.4) most of the cysteine residues present should be
unionized and not in the more reactive thiolate form 73 However, the formation of
the thiolate ion by cysteine residues may be promoted by the three-dimensional
interactions between cysteine and any surrounding basic amino acid residues. 74
Because of the softness of these thiol residues, cysteines have become a major
site of interest in regards to formed protein adduct investigations.
Two key components of new drug discovery and development are HSAB
interactions and the potential for drug-protein adduct formation.75 Concern for
lack of protein-binding specificity and potential for unknown side effects has led
pharmaceutical companies to avoid drugs that show the capability for covalent
protein binding.76 Despite this, Robertson found in 2005 that 25 of 71 biological
targets examined were covalently bound by marketed drugs.77 Since so many
compounds are capable of these drug-protein interactions, some researchers
have begun exploring what are termed covalent inhibitors, or drugs which
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covalently bind to a protein causing inhibition.78 Whether protein adduction is the
desired outcome or a negative side effect, HSAB theory is key in the preliminary
steps of drugs development and discovery.
2.4.3 Glutathione
One prominently reactive biological thiol can be found as part of glutathione
(GSH), an endogenous tripeptide which plays an important role in the removal of
reactive oxygen species (ROSs) in the body. The structure of GSH consists of
glutamic acid, cysteine, and glycine, with a γ-peptide linkage between glutamic
acid and cysteine (See Figure 3). Endogenous concentrations of GSH in human
cells range up to 10 mM, with higher concentrations occurring in the liver. 79 The
free thiol moiety of GSH acts as a reactive nucleophilic site, and it has been
shown to covalently bind to electrophiles in vivo.80,81 The capability of GSH to
bind to reactive metabolites allows it to function as one of the primary cellular
defenses against electrophilic/oxidative stress and damage. Because of GSH’s
reactivity and prevalence in the body, GSH adducts have also been used as
markers to identify, analyze, and monitor exposure to and excretion of
compounds of interest.58,82-84 The chemistry and structure of GSH make it an
ideal candidate for a trapping agent when utilized in an in vitro metabolic
assay.85-87

19

Figure 3. The chemical structure of glutathione showing the appropriate charges on the
terminal carboxy groups and the amine group.

Modification of GSH by both licit and illicit drugs has been well-studied and
reported in the literature.56,61,84,88-92 The first recorded observance of a GSH
adduct with acetaminophen was reported by Dahlin et al. in 1984. They reported
that N-acetyl-p-benzoquinone imine (NAPQI), a reactive metabolite of
acetaminophen, was reduced and formed a covalent conjugate with the GSH,
although they could not confirm the presence of NAPQI in the assay.80 Work in
1988 by the National Institute of Environmental Health Sciences explored the
HPLC-MS analysis of GSH conjugates formed with compounds such as
acetaminophen and 3-methylindole.93 Fragmentation characterization of a GSH
adduct formed with a derivative of acetaminophen was performed in 1993 by
Ballie and Davis.94 Furthermore, a wide variety of licit drugs, such as troglitazone,
dantrolene and raloxifene90; nefazodone92; and clozapine, naproxen, and
ibuprofen88, have all been analyzed as GSH adducts.
Although not as widely studied as licit compounds or endogenous ROSs,
GSH adducts with common illicit drugs of abuse have been reported throughout
the literature. One predominant example is 3,4-
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methylenediaminemethamphetamine (MDMA). Ramaley et al., who explored the
in vitro metabolism of MDMA with GSH present in the assay, observed two
possible GSH adducts; one formed with MDMA and the other with the oxidized
catechol of MDMA, 3,4-dihydroxymethamphetamine.95 Meyer et al. further
explored the adduct forming capabilities of 15 methylenedioxy designer drugs,
including both MDMA and methylenediaminepyrovalerone (MDPV), and
characterized the major fragments for the observed adducts. 84 They were able to
successfully identify common fragmentation patterns which applied to
methylenedioxy designer drugs and their major metabolites. As previously
mentioned, work performed by Schneider and DeCaprio characterized the
covalent conjugates formed by GSH and the drugs morphine, cocaine, and
methamphetamine, and delved into the kinetics and electronics involved in the
formation of the observed adducts.56 Morphine is another commonly abused drug
which has a GSH adduct which has been observed. In 2005, Todaka et al.
reported a GSH adduct with morphinone, the major metabolite of morphine, for
the first time.58
2.4.4 Hemoglobin as a Target for Reactive Xenobiotics
Hemoglobin (Hb) is a protein found in high concentrations in erythrocytes (red
blood cells). The protein is used for the transport of oxygen and carbon dioxide
throughout the body. In adults, erythrocytes are produced in the bone marrow
through a process called erythropoiesis. Erythrocytes have a biconcave
symmetrical structure and contain no nucleus. Hemoglobin derives its name from
the two heme groups contained within its four globin protein subunits. Heme is an
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iron coordination complex, where the central iron atom is coordinated to the four
nitrogen atoms of a porphyrin ring system. The specific heme found in
hemoglobin is Heme B (Figure 4).

Figure 4. The porphyrin ring system found in the heme B iron complex of hemoglobin.

There are six potential subunits of the Hb protein, however at least 95% of the
Hb found in an adult human is made up of the two subunits alpha and beta. 96 The
amino acid sequences of the alpha subunit (Hbα) of Hb was first reported in
196297, with the beta subunit (Hbβ) sequence being published just one year later
in 196398. There are only three cysteine residues contained in Hb, Hb α104Cys,
Hb β93Cys, and Hb β112Cys. Of these residues, Hb β93Cys has been shown to be
the most susceptible to adduction by soft electrophiles, followed by Hb β 112Cys
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and Hb α104Cys , respectively.99 The lifespan of erythrocytes in human blood, and
thus of Hb, is approximately 120 days, implying that the maximum lifespan for an
adduct at any of these three cysteines would be 120 days.100
A key issue when utilizing hemoglobin adducts as exposure biomarkers is the
capability of xenobiotics to enter into the erythrocyte to interact with the
hemoglobin molecule. Erythrocytes generally travel through body about once
every minute, totaling about 250km throughout the lifespan of a single cell101,
meaning that there is ample opportunity for xenobiotics and their metabolites to
interact with the cells. While hemoglobin is contained within the cellular
membrane of the erythrocyte, studies have shown that many compounds are
capable of passing through this membrane to potentially reach the protein.101
There are several examples in the literature regarding uptake of chemicals by
erythrocytes, including cyclosporine A102, the carbonic anhydrase inhibitor MK927103, and chloroquine104. Although other factors, such as temperature and pH,
have been shown to play a role in the uptake of certain compounds by
erythrocytes105, the above mentioned species are all partitioned via passive
diffusion through the cellular membrane.101
Hemoglobin adducts have been utilized as biomarkers of exposure to
xenobiotics in the past. The compounds which have been studied up to this point
have primarily been focused on environmental exposure to toxic chemicals. In
vivo experiments in the early 1990s used rats exposed to over 40 arylamines,
including several pesticides, to analyze the adducts formed with
hemoglobin.106,107 These studies noted the potential for the use of hemoglobin
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adducts as a biomarker of exposure to toxic pesticides. The focus on arylamine
toxicity and adduct formation continued in 1996, when McClure et al. described
hemoglobin adducts formed with the herbicides propanil and fluometuron and
proposed a mechanism of adduction for these compounds.108 Another application
of hemoglobin adduct biomarkers is the exposure to chemical warfare agents, in
particular sulfur and nitrogen mustard gases. Sulfur and nitrogen mustards have
both been shown to bind covalently to hemoglobin at multiple nucleophilic
residues, including cysteine and terminal valine residues and to a lesser extent
histidine and lysine residues.73,109
2.5 LC-MS Analysis of Covalent Protein Modifications
Since peptides and proteins are non-volatile compounds and extracted
solutions of such compounds from biological matrices will contain hundreds to
thousands of components with varying masses, the mass spectrometric analysis
of such species generally requires LC separation prior to analysis. The LC
separation requires a liquid solution containing the analytes be passed through a
column packed with a sorbent material. As the solution passes through the
column, the analytes interact with the sorbent material, and the strength of these
interactions affects how quickly the analytes pass through the column. Thus, LC
is a means to separate compounds via overall retention times within the column.
Following LC separation, mass spectrometry (MS) is used to analyze the
compounds as they are eluted from the column. Mass spectrometry is the
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analysis of chemicals by a mass-to-charge ratio (m/z). Using the m/z, the
projected mass of a chemical species can be predicted.
Mass spectrometers can also provide information about the overall
structure of a compound using fragmentation produced by collision induced
dissociation (CID). The fragmentation resulting from CID is caused by high speed
collisions occurring between a neutral gas molecule and a chemical analyte in
the gaseous phase. When the molecules collide, kinetic energy from the neutral
gas is transferred to the analyte resulting in bond breakage. Fragmentation
patterns may be specific to certain functional groups or structural components.
The process of data collection for the precursor analyte and the fragments
produced by CID is referred to as tandem mass spectrometry, or MS/MS
analysis.
Two common mass analyzers for MS/MS are the triple quadrupole (QqQ)
and the quadrupole time-of-flight (QTOF). A QqQ MS, as the name suggests,
consists of three quadrupoles in series. The first of these quadrupoles (Q1), is
used to select which ions are allowed to pass through the instrument. The
second quadrupole (q or Q2), is used as a collision cell for CID to produce
characteristic fragments. The third quadrupole (Q3), is used to select which
specific fragments produced in the collision cell will pass through to the detector.
There are several scanning modes possible with a QqQ depending upon which
m/z ratios are selected, including as product ion scans, precursor ion scans
(PIS), neutral loss scans (NLS), and selected reaction monitoring or multiple
reaction monitoring (MRM) (Figure 5).
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Figure 5. This diagram shows the four major scanning modes for an LC-QqQ-MS system.

Of particular interest in the present research is the PIS, as certain
peptides such as GSH have specific fragmentation patterns which are indicative
of GSH adducts.110 Negative mode analysis of GSH-containing compounds
provides very characteristic fragments at m/z 306, 272, 254, 210, 179, 160, 143,
and 128, with more fragments possible depending upon the ionized molecule
mass, or [M+H]+, of the compound.88,110 For example, [M+H]+ - 273 refers to an
indicative fragment where the precursor adduct is missing a portion with a m/z of
273. These specific fragmentation patterns of some peptides, in particular GSH,
allows for more facile examination of these species than when utilizing positive
ionization.
The QTOF mass analyzer consists of an initial quadrupole for ion
selection in tandem with a time-of-flight (TOF) chamber. All ions that pass
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through the collision cell enter the chamber are given the same kinetic energy in
a single direction by the orthogonal accelerator. The ions then all interact with the
reflectron, which forces the ions back to the detector (Figure 6). This particular
means of compound separation allows for high mass resolution and mass
accuracy, which is helpful when analyzing complex peptide mixtures and is
necessary for protein analysis.111,112

Figure 6. Schematic for a generic QTOF instrument, showing the quadrupole for ion
selection (Q1), the collision cell (q2), orthogonal accelerator, reflectron, and detector.112
The gas used in the collision cell for this research was N2.
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2.6 Bottom-Up Proteomics
The MS analysis of proteins such as Hb is generally divided into three
categories: top-down proteomics, middle-down proteomics, and bottom-up
proteomics (Figure 7). Top-down proteomics refers the analysis of proteins by
introducing a whole protein into the mass spectrometer and then fragmenting the
protein into peptides via CID. The peptides are then analyzed to determine the
overall structure and sequence, thus identifying the protein and its modifications.
Middle-down proteomics utilizes a proteolytic digestion to break down the protein
into mid-range molecular mass peptides before introduction into the mass
spectrometer. The use of tandem mass spectrometry (MS/MS) allows for
fragmentation of the enzymatically-produced peptides, and these data can
provide insight into the amino acid chains which makes up the peptides. Bottomup proteomics is very similar to middle-down proteomics, except that it uses a
proteolytic enzyme to break the protein into much smaller peptide chains. These
are more useful than the mid-range peptides when the protein being analyzed is
well-characterized and the sequence is already known.
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Figure 7. This diagram shows the general procedures for top-down, middle-down, and
bottom-up proteomics.113

When a proteolytic enzyme with a well-characterized cleavage pattern,
such as trypsin, is used for the protein digestion prior to analysis in bottom-up
proteomics, the resulting peptides can be analyzed with a high degree of
accuracy. Trypsin is an enzyme that cleaves peptides at the carboxylic end of
both lysine and arginine residues, except when followed by proline, with very
high specificity.114 This specificity implies that a protein with a known amino acid
sequence, such as Hb, will have a very predictable and reproducible collection of
peptides produced by a trypsin digestion. Trypsin also produces a very
manageable average peptide length of approximately 14 residues114, suggesting
that many of the produced peptides would be in a mass range most suitable for
bottom-up proteomics. For example, the tryptic hemoglobin peptide containing
Hb β93Cys is GTFATLSELHCDK, containing just 13 amino acids.
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2.6.1 LC-MS Peptide and Protein Analysis
Peptides fragment in specific patterns following CID. These fragmentation
patterns are well-documented in the literature and are relatively straight-forward
with few exceptions.112 The fragmentation along the peptide backbone can be
used to determine amino acid sequences and alterations (adduction) to the
specific amino acids of a known sequence. As can be seen in Figure 8, the
fragments are given the nomenclature of a,b,c (if the charged is maintained on
the N-terminus) or x,y,z (if the charge is maintained on the C-terminus),
depending upon the cleavage of the peptide bond. Of these formed fragments,
the most commonly observed are the “y” and “b” fragments, or the fragments
formed by the cleavage of the peptic bond between the carbonyl group and the
amine.

Figure 8. Peptide fragmentation patterns labeled with the common “a,b,c” and “x,y,z”
nomenclature.
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2.7 In Vitro Metabolic Assays
The formation of drug metabolites in an in vitro system may be monitored
by a metabolic assay system. Such metabolic assays mimic the natural
metabolism processes a xenobiotic may undergo in the human body. 45 In vitro
metabolic assays are typically used in pharmaceutical development to
characterize stable and reactive drug metabolites formed by natural metabolic
processes found in the human body.45,115 The most common types of in vitro
metabolic assays utilize homogenized liver fractions containing various enzymes
responsible for metabolism. These fractions include the S9 fraction, cytosol, and
human liver microsomes (HLM). The S9 fraction is the supernatant produced
from initial low speed centrifugation of a liver homogenate. When the S9 fraction
is then centrifuged at higher speed (100 x g), the supernatant consists of the
cytosolic fraction while the pellet consists of “microsomes” derived from rough
endoplasmic reticulum.. Human liver microsomes (HLM), the metabolic system
utilized in this research, contains a high concentration of the CYP enzymes
responsible for Phase I metabolism described in section 2.2.1.
2.7.1 In Vitro Metabolic Trapping Assays
As described previously, when certain xenobiotics are metabolized,
reactive intermediates may also be formed, which may then modify nearby
macromolecules to form covalent adducts, primarily through electrophilicnucleophilic interactions.116,117 The formation of these modifications can create a
potential for organ-specific toxicity118,119 or, alternatively, can be innocuous. In
either case, such adducts may also serve as biomarkers of exposure.88 Metabolic
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trapping assays have been widely employed to study these possibly harmful
products in vitro, particularly in pharmaceutical development where there is a
need to identify the potential for reactive metabolite production in candidate
drugs.89,120 Such assays are designed to mimic Phase I and II metabolic
processes in human cells.45 When a metabolic assay is used for the purpose of
examining reactive metabolite formation, a trapping agent must be added as a
target for covalent modification.121 Trapping agents are typically any one of
numerous, primarily nucleophilic and generally small, molecules that can bind
covalently to reactive intermediates, preventing further metabolism and
preserving the structure of the otherwise unstable compound.61 Examples of
trapping agents used in these assays include glutathione (GSH)89,122, Nacetylcysteine61, and cyanide45, with the emphasis of this research being placed
on GSH. Additionally, larger trapping agents may be used, such as larger
peptides or whole proteins containing at least one nucleophilic site.

32

2.8 Research Objectives
This research was performed to test three hypotheses:
1. In vitro metabolic assays can successfully mimic in vivo metabolic
processes for relevant drugs of abuse.
2. Small peptides used as trapping agents in in vitro metabolic assays can
form covalent adducts with reactive metabolites of drugs of abuse.
3. These same adducted moieties can also be observed on whole proteins.
The primary objective of this research was to observe and characterize covalent
adducts with hemoglobin by reactive metabolites of certain drugs of abuse. This
objective was accomplished by completing the following three tasks.
1. Create and optimize a LC-MS/MS method for the detection and
characterization of drugs of interest and stable drug metabolites.
Specifically:
a. Create a LC-MS method to determine the retention time of the
parent drugs.
b. Using retention times, create a targeted MS/MS method to
determine and analyze common transitions for each parent drug.
c. Perform metabolic assays and identify and confirm metabolites
formed under assay conditions via LC-MS/MS.
2. Create and optimize a LC-MS/MS method for the detection and
characterization of reactive drug metabolites. Specifically:
a. Optimize a metabolic trapping assay using glutathione as a
nucleophilic trapping agent.
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b. Analyze MS and MS/MS data collected from GSH studies to
compile a list of possible adducts formed.
c. Determine plausible structures for observed adducts using MS and
MS/MS data.
3. Confirm adduction in purified proteins by drugs of interest.
a. Optimize a metabolic trapping assay to incorporate hemoglobin as
a trapping agent.
b. Analyze Hb trapping assays to determine sites of adduction and
number of expected adducts.
c. Confirm adduction with Hb by collecting MS/MS data for the Hb
tryptic peptides.
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3. Methodology
3.1 Instrumentation
Analysis by LC-QqQ-MS was performed on an Agilent 1290 Infinity ultrahigh performance liquid chromatography (UHPLC) coupled to an Agilent 6460
QqQ MS. Analysis by LC-QTOF-MS was performed on an Agilent 1290 Infinity
UHPLC coupled to an Agilent 6530 QTOF MS. Both positive and negative ion
scanning modes were used with the LC-QTOF-MS, while only negative mode
ionization was used for the LC-QqQ-MS. Both instruments utilized Agilent Jet
Stream electrospray ionization (ESI). The column utilized for both instruments
was an Agilent Zorbax Eclipse Plus C18 rapid resolution HD. Elution solvents,
injection volumes, and LC pump parameters varied for experiments and are
discussed below. Elution solvent flow rate was 0.3 mL/min. for all runs. Data
acquisition for the QqQ and QTOF was performed using Agilent’s MassHunter
Acquisition software (version B.06.00 for both systems). Data analysis was
performed using Agilent’s MassHunter Qualitative software (version B.07.00),
with supplementation by Agilent’s BioConfirm software (version B.08.00).
3.2 Drug Selection
The drugs of interest in this study were selected based on a known
potential for addiction/dependence and prevalent usage, while also ensuring that
various structural and pharmacological classes of drugs were represented in the
final list. All of the selected drugs are examples of compounds which may be
identified in authentic specimens from law enforcement cases, rehabilitation
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centers, correctional facilities, and outpatient therapy. As mentioned in section
2.1, the drugs of interest selected for this study were α-pyrrolidinopentiophenone,
acetaminophen, alprazolam, buprenorphine, clozapine, cocaine, diazepam,
methadone, methamphetamine, methylenedioxymethamphetamine,
methylenedioxypyrovalerone, methylone, morphine, naltrexone, oxycodone, and
Δ9-tetrahydrocannabinol. The two positive control compounds selected for this
study are acetaminophen and clozapine, both of which have shown the capability
of binding to endogenous nucleophiles. Radiolabeled acetaminophen has been
shown to bind to the free cysteine in bovine serum albumin, with the adduct
being identified as 3-cystein-S-yl-4-hydroxyaniline.123 Additional studies by
James, et al. investigated the potential for liver induced toxicity by
acetaminophen-protein adducts.124 McGill, et al. reported that acetaminophenprotein binding is possible at subtoxic levels of administration and before levels
of glutathione, a generally more favorable target of electrophilic compounds,
were depleted.125 Both acetaminophen and clozapine have been shown to exhibit
affinities to covalently bind to glutathione on multiple occasions.110,126-128
3.3 Parent Drug Analysis
In order to determine the appropriate instrumental parameters for the
analysis of the metabolites formed by the drugs of abuse, the parent drugs were
analyzed for retention time and major fragments formed. Analysis of the parent
drugs was performed using LC-QTOF-MS using positive ionization and full scan
mode. Elution solvents for the parent drug analysis were A: 5 millimolar (mM)
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ammonium formate in water with 0.1% formic acid and B: acetonitrile with 0.1%
formic acid. Pump parameters were as follows: 0-2 min. 5% B, 2-5 min. ramp
from 5% B to 50% B, 5-7 min ramp from 50% B to 100% B, hold at 100% B until
10 min., followed by a two min. post-run for re-equilibration of the instrument to
the starting configuration. A one part per million (ppm) solution in methanol was
created for each of the 16 drugs used in this study (Table 2), except for APAP,
which due to solubility issues was dissolved in water, and THC which was
dissolved in ethanol. A 5 µL aliquot of each drug-containing solution was injected
into the mass spectrometer, and the corresponding retention time was collected.
Once retention times were collected for all parent drugs, mixtures were
created containing three of the parent drugs with differing retention times.
Targeted scan mode MS/MS analysis was performed on these five mixtures to
collect major transitions using the same LC-MS parameters as the retention time
collection. Transitions were collected at 10, 20, and 40 electron volts (eV) to
ensure that complete fragmentation was achieved for all drugs. These scans
were performed in triplicate, and the three consistently most prominent fragments
were recorded.
3.4 Drugs of Abuse Stable Metabolites
3.4.1 Stable Metabolite Formation
Stable metabolites were analyzed for clozapine, which has prominently
formed and well-established stable metabolites.129 These metabolites were
studied to aid in the optimization of parameters for the in vitro metabolic assay
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required for later research. Briefly, the stable metabolite assay consisted of final
concentrations of 100 µM drug of interest, 1 mg/mL HLM, 2 mM nicotinamide
adenine dinucleotide phosphate (NADPH), 3 mM magnesium chloride (MgCl2), 3
mM glucose-6-phosphate (G6P), and 0.4 U/mL glucose-6-phosphate
dehydrogenase (G6PD) with a total assay volume of 125 µL in 50 mM sodium
phosphate buffer pH=7.4. A high drug concentration and the use of an activating
cofactor regeneration system were employed to ensure maximum formation of
metabolites. The assay components were combined in a microfuge tube and
briefly vortexed to ensure uniformity. The vials were then incubated at 37°C for
two hours. Following incubation, enzymatic activity was ceased by the addition
of 25 µL ice-cold acetonitrile (6% acetic acid). The vials were then centrifuged at
15,000 x g at 4°C for 30 minutes. After centrifugation, a 100 µL aliquot was
removed and placed into a clean LC-MS vial for analysis.
3.4.2 Stable Metabolite Analysis
Stable metabolite analysis was performed using LC-QTOF-MS using
positive ionization and full scan mode. Elution solvents for the parent drug
analysis were A: 5 millimolar (mM) ammonium formate in water with 0.1% formic
acid and B: acetonitrile with 0.1% formic acid. Injection volume was set to 1 µL.
Pump parameters were as follows: 0-2 min. 5% B, 2-5 min. ramp from 5% B to
50% B, 5-7 min ramp from 50% B to 100% B, hold at 100% B until 10 min.,
followed by a two min. post-run for re-equilibration of the instrument to the
starting configuration. Collected spectra were compared to negative controls
without a metabolic system, and the new peaks were analyzed.
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3.5 Metabolic Trapping Assay with Glutathione
Once the in vitro assay parameters were optimized, adduction by reactive
metabolites with GSH was studied. This process required a similar in vitro assay
as the stable metabolites, but with the addition of a trapping agent. Briefly,
components of the in vitro trapping assay were combined in a total assay volume
of 125 µL of 50 mM sodium phosphate buffer, pH 7.4, at the following final
concentrations: 1000 µM drug of interest, 1 mg/mL HLM, 3 mM MgCl2, 2 mM
NADPH, 3 mM G6P, 0.4 U/mL G6PD, and 2 mM GSH. Drug of interest is added
to a clean microfuge tube and solvent is removed via vacufuge. Assay
components without GSH were then combined in the microfuge vial and vortexed
briefly to ensure uniformity, followed by a pre-incubation of 15 min at 37°C. The
GSH was then added to complete the assay and achieve final assay volume, and
vials were once again vortexed to ensure proper mixing. Incubation then ensued
at 37°C for 3 h. Upon completion of incubation, vials were immediately
centrifuged at 15,000 × g at 4°C for 30 min. Following centrifugation, 100 µL
aliquots of supernatant were removed from each vial and placed in separate,
clean LC vials. This assay method is illustrated in Figure 9.
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Figure 9. Illustration of the metabolic trapping assay method utilizing GSH as a trapping
agent.

3.5.1 Glutathione Adduct Analysis
Preliminary analysis of GSH adducts was performed using positive
ionization and full scan mode on the LC-QTOF-MS. Elution solvents for the
parent drug analysis were A: 5 millimolar (mM) ammonium formate in water with
0.1% formic acid and B: acetonitrile with 0.1% formic acid. Injection volume was
set to 1 µL. Pump parameters were as follows: 0-2 min. 5% B, 2-5 min. ramp
from 5% B to 50% B, 5-7 min ramp from 50% B to 100% B, hold at 100% B until
10 min., followed by a two min. post-run for re-equilibration of the instrument to
the starting configuration.
Negative mode analysis work began with the LC-QQQ-MS and used PIS.
Elution solvents for GSH adduct analysis in negative mode were A: water with
0.1% acetic acid, and B: 95% acetonitrile, 4.9% water, and 0.1% acetic acid.
The pump timetable was as follows: 5% B hold for 1 min, 5% to 100% B ramp
from 1 to 14 min, 100% B hold for 2 min, followed by a 3-min post-time for
reequilibration to initial conditions for next injection. The precursor ion scan was
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set to identify the precursor ions for any fragments with m/z 272, a common and
indicative product of GSH, corresponding to GSH less the sulfur atom.110 The
scan took place over the mass range m/z 400-800 to avoid interference from
unreacted GSH ([M-H]- m/z 306) and to maximize detection of likely adducts for
all drugs. Peaks were determined to be potentially significant if they had an
unscaled abundance higher than 1000 counts. All peaks determined to be
potentially significant for each drug had their m/z recorded. The extracted ion
chromatogram (XIC) MS spectrum was also collected for each potentially
significant peak. The XIC was examined for characteristic fragmentation
common to GSH-containing compounds.
3.5.2 Glutathione Adduct Confirmation
Negative mode analysis was continued on the LC-QTOF-MS. Initial analyses
by QTOF-MS were performed using full scan mode. In full scan mode, the mass
range was again restricted to m/z 400-800 with fragmentor voltage set to 120 V
and no collision induced dissociation. Data were collected for this mass range
over the entire run time and any prominent peaks of interest were recorded and
then analyzed using targeted MS/MS. In targeted mode, MS/MS data were
collected only for the molecular ion peaks of interest, with the mass range set to
m/z 100-800 to allow for smaller identifying fragments to be recorded at collision
energies of 10, 20, and 40 eV to allow for full visualization of fragments formed.
Compounds with fragmentation consistent with masses commonly seen for
fragmentation of GSH were recorded and compared to the list previously
compiled from the initial QQQ-MS analyses. In addition, several putative adducts
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not seen during initial low-resolution MS analysis were observed by QTOF-MS.
The compounds deemed of interest also showed the GSH-characteristic ion with
the mass of m/z (M-H+)- - 272. As with the QQQ-MS studies, other ions
previously reported to be characteristic of GSH adducts in negative mode ESI
were typically present.
3.6 Identification of Glutathione Adduct Structures
Adduct structures were proposed based on accurate mass data for the
molecular ion of each drug-GSH adduct and for major MS/MS fragments.
Masses consistent with previously reported adducts were assigned the
respective structures published in the literature. For novel adducts, a list of
metabolites potentially formed in situ was compiled using published metabolism
data as available and, where not available, the structure of the parent drug was
altered using common metabolic processes via ChemDraw Prime software
(PerkinElmer, version 16.0) until a plausible adduct structure was created. For
this process, metabolic reactions that were examined included hydroxylation
(along with NIH shift), O- and N-demethylation, oxidation/reduction, and loss of
reactive moieties, as these are common for Phase I metabolic pathways.61
Structures associated with more than one metabolic transformation were also
considered. The final theoretical adduct list therefore consisted of multiple target
structures for each drug.
Calculated molecular ion masses of the theoretical adduct structures were
then compared to those observed in the QTOF-MS/MS analysis for each drug to
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identify tentative positive hits. For these compounds, MS/MS fragmentation data
were then utilized for further confirmation of adduct structure. Both GSH- and
drug-specific fragments were considered in this analysis for maximum confidence
in the resultant structural assignments. Where present, exact stereo- and
regiospecificity of the covalent adduct bond was not identified.
3.7 Adduction with Hemoglobin
The metabolic trapping assay with Hb as a trapping agent required some
initial optimization. The first utilized assay method involved a cup insert for
microfuge tubes with a dialysis membrane in the bottom, allowing for passive
diffusion of smaller molecules. These dialysis membrane cups had not been
used for this purpose, but were explored as an option because it would allow for
full separation of the HLM enzymes and the Hb protein without the need for
additional separation.
3.7.1 Hemoglobin Trapping Assay Method
Adduction with hemoglobin was performed using a trapping assay similar
to the GSH trapping assay followed by proteolytic digestion by trypsin to produce
smaller peptides. Briefly, components of the in vitro trapping assay were
combined in a total assay volume of 250 µL of 25 mM sodium phosphate buffer,
pH 7.4, at the following final concentrations: 500 μM test drug, 0.5 mg/mL HLM, 1
mM NADPH, 1.5 mM MgCl2, 1.5 mM G6P, 0.2 units/mL G6PD and 2.5 mg/mL of
a prepared human Hb solution (5 mg/mL Hb in 25 mM ammonium bicarbonate
buffer). Drug of interest is added to a clean microfuge tube and solvent is
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removed via vacufuge. Assay components were then combined in the microfuge
vial and vortexed briefly to ensure uniformity, the tube was then incubated with
agitation at 37°C for 6h. Following incubation, the vial was centrifuged for 30 min
at 100,000 x g at 4°C. After centrifugation, the supernatant was transferred into a
clean microfuge tube. A freshly-prepared 15 mM solution of iodoacetamide
(IAM) was then added, and the vial was incubated at room temperature in the
dark for 1 hr. Following incubation, intact Hb was extracted from the reaction
mixture via Amicon® Ultra 0.5 mL centrifugal filter spun at 15,000 x g for 10 min.
Hb was then collected into a new clean microfuge vial and reconstituted in a 1
mg/mL solution of CaCl2. A 0.25 mg/mL solution of trypsin was then added, and
the vial was incubated at 37°C for 16 h. The vial was then centrifuged for 30 min
at 100,000 x g at 4°C, and the supernatant collected and placed into a clean LCMS vial for analysis. An illustration of this metabolic trapping assay method is
found in Figure 10.

Figure 10. Illustration of the metabolic trapping assay method utilizing Hb as a trapping
agent.
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3.7.1 Hemoglobin Adduct Analysis
Analysis of the tryptic peptides was performed using LC-QTOF-MS
utilizing first full scan mode followed by Auto MS/MS scan mode with positive
ionization. The full scan mode consisted of no collision energy and only collected
MS data. The collision energy for the Auto MS/MS analysis was set using the
equation y=2x+20, where y is the collision energy and x is the mass of the parent
ion. The masses 121.0388 and 922.0098 were excluded from collection because
they are the masses of the reference ions used to maintain mass accuracy by the
instrument. The following parameters were used for both scan mode analyses.
Column temperature was controlled at 40°C. Elution solvents for the tryptic
peptide analysis were A: water with 0.1% trifluoroacetic acid and B: acetonitrile
with 4.9% water and 0.1% trifluoroacetic acid. Injection volume was set to 3 µL.
Pump parameters were as follows: 0-0.5 min. 10% B, 0.5-18 min. ramp from 5%
B to 50% B, 18-20 min ramp from 50% B to 100% B, hold at 100% B until 21
min., followed by a two min. post-run for re-equilibration of the instrument to the
starting configuration.
Analysis of the data collected for the peptide adducts was performed using
Agilent’s MassHunter BioConfirm software (version B.08.00). The workflow used
was the “peptide digest” method, the condition was “reduced”, the sequences
selected were the subunits Hbα and Hbβ, the enzyme selected was trypsin, and
the modifications were acetylation, hydroxylation, and any appropriate custom
modifications. The custom modifications were individually created for each drug
of interest based upon observed adducts from GSH studies and, where GSH
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data were unavailable, data collected from adduction studies using a synthetic
peptide (manuscript in progress by Moller, et al). For the MS studies, once the
workflow was run the predicted modifications were analyzed, and any potential
drug adducts were recorded. For the Auto MS/MS studies, the spectra were
collected, compared to the theoretical peak list supplied by Protein Prospector,
and confirmed peaks were recorded. Peaks were considered a close match if the
observed mass was within 0.1 Daltons (Da) of the hypothetical mass reported in
the theoretical peak table. Peaks were considered a possible match if the mass
differential was <0.5 Da. All peaks with a mass differential ≥0.5 Da were
excluded. The workflow for the analysis of the Hb peptide adducts can be found
in Figure 11.

Figure 11. Flowchart of workflow for Hb peptide adduct analysis.
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4. Results
4.1 Task 1: Create and optimize a LC-MS/MS method for the detection and
characterization of drugs of interest and stable drug metabolites.

4.1.1 Parent Drug Retention Times
Optimization of the acquisition method to analyze retention times of the
parent drugs ensured that a single method could be used for the analysis of all of
the drugs of interest. Solutions of individual drugs were injected into the
instrument and the exact mass ([M+H]+) and retention times were recorded
(Table 7). The overlaid total ion chromatograms (TICs) of 13 of the drugs of
interest can be found in Figure 12. Several of the compounds had retention times
very similar to others, and these drugs were separated into different mixtures for
the next step of this task. The drugs of interest missing from Figure 12 were
omitted because their TICs were recorded on a different date than the 13 drugs
pictured. The positive controls APAP and CLZ were recorded separately (Figure
13), and THC needed to be dissolved in ethanol (Figure 14). Additionally, THC
could not be identified as a peak without the use of the Find by Formula feature
of the MassHunter Qualitative software, which targets the specific mass of a
chemical formula and extracts corresponding peaks from the TIC. This method
was utilized because THC exhibited poor ionization in positive mode, and
coeluted with much of the material being flushed through the column by the high
organic percentage of mobile phase at the end of the run (Figure 14). Because of
these issues with the analysis of THC, the extracted ion chromatogram (XIC) for
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THC was utilized to determine the retention time, which was then added to the
complete list of the drugs.

Figure 12. A zoomed in portion of the overlaid TICs for α-PVP, ALP, BUP, COC, DZP,
MDMA, MDPV, META, METH, METY, MOR, NAL and OXY. The peak at approximately 2.1
min. found in every spectrum is carryover from APAP.

Figure 13. TICs for CLZ (top) and APAP (bottom), the two positive controls, used to collect
their respective retention times.
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Figure 14. TIC (top) and XIC (bottom) for THC, showing the retention time for THC.

4.1.2 Parent Drug Fragmentation
After the collection of all retention times and exact masses observed by
the instrument for each parent drug, the five mixtures of non-coeluting parent
drugs were analyzed. The instrumental method used for analysis of the mixtures
utilized targeted MS/MS mode, but all other parameters remained the same. The
mixtures created can be found in Table 6.
Mixture

Drugs Included

Mixture #1

APAP, METH, COC

Mixture #2

MDMA, α-PVP, DZP

Mixture #3

META, METY, MDPV

Mixture #4

ALP, MOR, OXY

Mixture #5

BUP, NAL, THC

Table 6. Mixtures of parent drugs created to collect transitions
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CLZ was not included in the original mixtures, but was run individually.
The TIC for each mixture (Figure 15) was analyzed using the Find by Targeted
MS/MS feature on Masshunter Qualitative software. The collected spectra for
each collision energy (10, 20, or 40 eV) were analyzed separately to ensure that
a complete list of fragments could be identified. It was necessary to collect these
data so it would be possible to apply the same fragmentation patterns to
proposed adducts at later stages of this research. The MS/MS data collected for
the parent drugs can be found below in Figure 16. Table 7 was created by
combining the information from the retention time experiments and the transition
experiments for all of the drugs of interest. Many drugs had transitions with the
same m/z, but are distinguishable by the other recorded transitions or retention
times.
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Figure 15. Targeted MS/MS TICs for the five mixtures of the parent drugs.
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Figure 16. MS/MS data for the parent drugs. The data are shown at 10 eV (top), 20 eV
(middle), and 40 eV (bottom) for each drug.
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Formula

[M+H]+

Ret. Time

Tran. 1

Tran. 2

Tran. 3

α-PVP

C15H21NO

232.170

4.48

161.094

126.126

91.053

APAP

C8H9NO2

152.071

2.14

110.060

93.034

65.039

ALP

C17H13ClN4

309.090

5.58

281.070

274.117

205.073

BUP

C29H41NO4

468.311

5.18

414.257

396.213

55.054

CLZ

C18H19ClN4

327.147

4.88

270.089

227.045

192.075

COC

C17H21NO4

304.154

4.59

182.115

105.033

82.064

C16H13ClN2O 285.079

6.28

193.089

154.042

91.054

DZP
MDMA

C11H15NO2

194.118

3.93

163.074

135.043

77.038

MDPV

C16H21NO3

276.159

4.58

205.083

175.072

126.126

META

C21H27NO

310.217

5.57

265.156

105.033

77.038

METH

C10H15N

150.128

3.79

119.083

91.053

65.038

METY

C11H13NO3

208.097

3.56

190.085

160.075

132.080

MOR

C17H19NO3

286.144

1.41

229.085

201.090

165.069

NAL

C20H23NO4

342.170

3.82

324.156

267.112

55.054

OXY

C18H21NO4

316.154

3.78

298.141

256.132

241.108

THC

C21H30O2

315.232

7.78

259.174

193.126

135.119

Table 7. Retention time and fragmentation data collected for all 16 drugs of interest in this
research. Retention time is in minutes. Transitions collected were the three most
prominent across all collision energies.

4.1.3 Stable Drug Metabolites
Attempts to simplify the metabolic assay used for the stable drug
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metabolites involved excluding the regeneration system for the NADPH. Initial
experiments analyzing the stable metabolic assay did not utilize G6P and G6PD,
and therefore produced poor results. The addition of the regeneration system
yielded significantly better results and were then applied to the metabolic assay
with clozapine.
When utilizing clozapine for metabolism studies, there are generally two
major metabolites produced, clozapine N-oxide and N-desmethylclozapine
(Figure 17).129 Following the in vitro metabolic assay performed, there were two
peaks present in the TIC which were not present in the negative controls (Figure
18). Both of these new peaks corresponded to the major metabolites for
clozapine, with m/z of 343.1182 for clozapine N-oxide and 313.1220 for Ndesmethylclozapine. Their XIC data can be seen in Figure 19.

Figure 17. Two major metabolites for clozapine, clozapine N-oxide (left) and Ndesmethylclozapine (right) with their exact masses.

59

Figure 18. The TICs for the in vitro metabolic assay for clozapine (top) and the negative
control with no metabolic system (bottom). The two new peaks are labeled with their
corresponding metabolite.

Figure 19. XIC data for N-desmethylclozapine (top) and clozapine N-oxide (bottom).

The stable metabolite data for COC also showed two prominent metabolites,
benzoylecgonine and cocaethylene. These data can be seen in Figures 20 and 21. The
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observation of the metabolites for both CLZ and COC implied that the metabolic
system utilized would be able to successfully produce the expected metabolites
of the drugs of interest.

Figure 20 The TICs for the in vitro metabolic assay for COC; the two new peaks are labeled
with their corresponding metabolite.

Figure 21 XIC data for cocaethylene (top) and benzoylecgonine (bottom).
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4.1.4 Task 1 Discussion
The purpose of this task was to characterize the parent drugs of abuse
selected for this study and to assess the effectiveness of the in vitro metabolic
assay. To discover how the drugs would behave during the instrumental analysis
procedure, retention times were determined for all of the drugs. The positive
control acetaminophen is not completely soluble in methanol. This led to
acetaminophen being retained on the column and eluting into subsequent
sample runs taken that day, as can be seen in Figure 12. Fortunately, this did not
interfere with the retention times of any of the other drugs of interest. THC also
did not elute at a time similar to the other compounds, and instead was detected
towards the end of the run when a high percentage of organic mobile phase was
running through the column. This led to no visible peak for THC, a problem which
was remedied by the Find by Formula feature of MassHunter’s Qualitative
software (Figure 14). This may be due to THC being poorly ionized in positive
mode, with negative ionization generally being favored for THC analysis. 130
The fragmentation collected for each drug of interest was obtained in
hopes that it would provide insight into the possible fragmentation patterns of any
adducted moieties in later studies. All fragmentation data was collected in
positive mode, as many of the drugs experience poor ionization using negative
mode analysis. While analysis shifted from positive to negative ionization with the
GSH adduct studies, the fragmentation collected in Task 1 will be useful in any
future GSH research utilizing positive ionization mode analysis of adducts.
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In order to progress to the subsequent tasks of this research, stable
metabolite analysis was only preformed using clozapine. While clozapine may
have as many as five observed stable metabolites, clozapine N-oxide and Ndesmethylclozapine are the most prevalent and were the two metabolites
pursued in this task.131 These two stable metabolites have been observed in
plasma at concentrations approximately the same as the parent drug.132 The
identification of these two compounds allowed for advancement to the
implementation of reactive metabolite assays containing trapping reagents.
4.2 Task 2: Create and optimize a LC-MS/MS method for the detection and
characterization of reactive drug metabolites.

4.2.1 Metabolic Trapping Assay Optimization
Optimization of the in vitro assay system required numerous factors to be
examined. Incubation times of 1, 3, 6, and 12 h were examined, with 3 h
determined to be optimal for maximum production of primary metabolites and
minimal formation of secondary products. As reported by other investigators84,
glutathione-S-transferase (GST) was included in several trials to determine if its
presence would aid in the formation of adducts with GSH. However, there was
no observed increase in adduct formation, and GST was therefore eliminated
from the protocol for simplicity. The addition of G6P and G6PD provided a
regeneration system for NADPH which allowed for optimal enzymatic activity for
the duration of the incubation. Initial trials were conducted with a drug: GSH
molar ratio of 1:20, however this was later changed to 1:2 (final concentration as
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stated in Methods) by increasing the concentration of the drug of interest in order
to maximize the concentration of the reactive metabolites formed. Even though
this is not an accurate approximation of biologically relevant drug concentrations,
it was determined that this amount would provide the greatest opportunity for
adduct formation.
4.2.2 MS and MS/MS Analysis of Glutathione Adducts
Figure 22a shows an example of a product ion TIC for the positive control drug
APAP. A large peak is present at RT ~2.6 min; the inset shows numerous
additional potentially relevant peaks at lower abundances. XIC analysis of
APAP-adducted GSH (Figure 22b) revealed one major product at RT 2.68 min
with m/z 455 and a minor product at RT 2.36 min with m/z 471. Bot of the APAPGSH adducts identified in this experiment have been previously reported.80,88
The precursor ion scan TIC and XIC data for the remaining drugs can be found
in Appendix 1.
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Figure 22. (A) TIC of APAP+GSH collected by product ion scan mode via LC-QqQ-MS in
negative ionization mode. Inset is zoomed-in portion around the base of the major peak,
showing multiple peaks with lesser intensities. (B) XICs for ions at m/z 471 and 455, the
two relevant peaks of interest from the TIC.

Using this approach, a total of 20 potentially significant GSH adduction
products were identified by LC-QqQ-MS/MS analysis for 10 of the 16 drugs
examined, including APAP, CLZ, COC, DZP, MDMA, MDPV, MOR, NAL, OXY,
and THC. Multiple adduct structures were also observed for a number of drugs.
In contrast, GSH adducts were not observed for ALP, BUP, DZP, META, METH,
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and METY under the conditions used in the study. Target products detected by
low resolution MS were then further examined using high resolution LC-QTOFMS/MS analysis as described below. These potential adducts, and those
observed by LC-QTOF-MS/MS analysis, are summarized in Table 8.

Table 8. Theoretical adduct masses collected via QQQ-MS/MS and QTOF MS/MS.
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Figure 23 shows the high-resolution mass spectrum of GSH, with
corresponding fragment structures indicated. Table 9 presents HRMS data
(molecular formula, molecular ion and characteristic fragment ions, and proposed
composition) for all GSH adducts detected in the study, along with literature
reference if previously reported. The presence and relative abundance of
characteristic GSH fragments (i.e., “b”, “f”, “i”, and “k” ions) and fragments
associated with drug still bound to GSH (i.e., “d” and “j” ions) provided important
data to further elucidate adduct identity and location of the drug-thiol
linkage(Figure 24).88 In addition, ions associated with fragmentation within the
drug moiety itself were occasionally observed. Structural elucidation was
facilitated by the generation of fragments at collision energies of 10, 20, and 40
eV (i.e., top, middle, and bottom panels of each adduct MS/MS spectrum in
Figure 25). All MS/MS data for adducts previously reported in the literature are
confirmed in Figure 26.
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Figure 23. LC-QTOF-MS/MS data collected for glutathione. The peaks labeled all
correspond to a known characteristic GSH peak. Negative ionization structures for each
peak are provided for each peak.

Figure 24. Detailed breakdown of the nomenclature used for the fragmentation of the GSH
adducts. Data presented are from Xie et al.88
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Figure 25. MS/MS spectra for all 12 previously unreported adducts. The molecular ion is
represented in blue, GSH-specific peaks in green, and structurally significant peaks for
GSH-containing compounds in red. Proposed structures for 9 of the 12 adducts are also
shown with GSH linkage indicated.
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Figure 26. MS/MS data collected for all previously reported GSH adducts
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Drug

Formula

Composition

Ions Observed

C10H17N3O6S

GSH

306.095, 272.106(k), 254.094, 210.103, 179.059, 160.020, 143.058(b), 128.046(f)

APAP1

C18H24N4O8S

D+GSH-2H

APAP2

C18H24N4O9S

D+GSH+O-2H

CLZ1

C28H34ClN7O6S

CLZ2

Reference

455.089, 272.089(k), 254.078, 210.088, 182.028(d), 143.045(b), 128.046(f)
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471.119, 272.088(k), 198.025 (d), 143.045(b), 128.045(f)

82

D+GSH-2H

630.194, 357.095(d), 272.089(k), 254.078, 143.046(b)

75

C28H36ClN7O7S

D+GSH+O

648.198, 272.089(k), 143.046(b)

75

CLZ3

C23H24ClN5O7S

D+GSH+O-C5H10N2

COC1

C27H38N4O11S

D+GSH+O

625.230, 565.055, 384.821, 306.080(i), 272.090(k), 194.950, 143.046(b)

DZP1

C26H30ClN5O8S

D+GSH+O

606.154, 588.142, 315.039, 272.088(k), 258.013, 210.089, 143.046(b)

MDMA1

C20H30N4O8S

D+GSH-CH2

485.189, 272.090(k), 212.771(d), 143.047(b), 128.045(f)
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MDMA2

C21H30N4O8S

D+GSH-2H

497.131, 272.091(k), 254.085, 143.047(b), 128.046(f)

78

MDMA3

C19H25N3O9S

D+GSH+O-C2H7N

470.140, 436.793, 272.090(k), 197.030(d), 143.046(b), 128.045(f)
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MDPV1

C25H36N4O9S

D+GSH-CH2

567.238, 294.118(d), 272.091(k)

78

MDPV2

C21H29N3O9S

D+GSH-C5H8N

498.172, 272.089(k), 225.060(d), 143.046(b), 139.995

None

MDPV3

C21H29N3O10S

D+GSH+O-C5H7N

514.168, 378.808, 272.103(k), 241.068(d), 143.056(b)

None

MOR1

C27H34N4O9S

D+GSH-OH

589.219, 316.102(d), 306.077(i), 272.089(k), 210.089, 143.046(b), 128.045(f)

NAL1

C30H38N4O10S

D+GSH-2H

645.249, 306.094(i), 272.105(k), 210.089, 143.057(b), 128.046(f)

C30H40N4O11S

D+GSH+O

663.260, 390.157(d), 358.184(j), 306.093(i), 272.105(k), 210.089, 143.057(b),

548.101, 275.005(d), 272.095(k), 143.046(b)

NAL2

None
57
None

54
None

None
128.046(f)

OXY1

C28H36N4O10S

D+GSH-2H

619.208, 408.012, 306.077(i), 272.958(k), 210.089, 143.057(b), 128.046(f)
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None

OXY2

C28H34N4O11S

D+GSH+O-4H

633.223, 306.076(i), 272.088(k), 210.089, 143.057(b), 128.046(f)

None

THC1

C31H45N3O9S

D+GSH+O-2H

634.306, 361.205(d), 306.095(i), 272.106(k), 210.091, 143.058(b), 128.046(f)

None

C31H45N3O10S

D+GSH+O2-2H

650.301, 377.199(d), 343.193(j), 306.094(i), 272.106(k), 210.091, 143.057(b),

THC2

None
128.046(f)
C31H45N3O11S

D+GSH+O3-H

666.297, 393.195(d), 359.190(j), 306.094(i), 272.106(k), 210.091, 143.057(b),

THC3

None
128.046(f)

THC4

C31H41N3O12S

D+GSH+O4-4H

678.304, 306.095(i), 272.106(k), 210.091, 143.058(b), 128.046(f)

a

Molecular ion in bold; letters in parentheses refer to characteristic GSH fragments according to nomenclature of Xie et al. (2013).

b

Literature reference for previously reported adduct; none – not previously reported.

Table 9. Summary of fragmentation of all GSH adducts observed.
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None

4.2.3 Glutathione Adduct Structure Identification
As an example of the procedure used to confirm GSH adduct formation
and identity based on HRMS data, the molecular ion peak observed at m/z
455.089 for APAP was consistent with a previously reported adduct of the parent
drug with GSH (APAP1; Figure 27a and Table 9) Major fragment ions for this
adduct included the molecular ion (m/z 455.089), five fragments specific to GSH
(m/z 272.089, 254.078, 210.088, 143.045, 128.046)88, and a fragment
corresponding to the drug moiety bound to the sulfur of GSH (m/z 182.028). A
second, less intense molecular ion peak for an acetaminophen-GSH adduct
(APAP2) was observed at m/z 471.119, along with three fragments consistent
with GSH modification (m/z 272.088, 143.045, and 128.045) in addition to a
fragment corresponding to the drug moiety bound to the sulfur of GSH (m/z
198.025) (Figure 27b and Table 9). To determine potential structures for this
adduct, the parent drug was subjected to manual metabolic modification analysis
using ChemDraw Prime software (PerkinElmer, version 16.0) to produce a list of
likely alterations occurring from Phase I metabolism. This analysis indicated that
hydroxylation of the phenyl ring would produce calculated molecular ion and
fragment masses consistent with those observed. This proposed most likely
adduct structure has also been previously reported.88
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Figure 27. MS/MS data collected for APAP1 and APAP2.

The same general procedure was repeated for all detected putative drugGSH adducts. Figure 25 shows QTOF MS/MS spectra and proposed structures
for all GSH adducts identified in the present study that have not been previously
reported in the literature. For clozapine, three GSH adducts were detected.
Data for two of these (CLZ1 and CLZ2) are consistent with adducts previously
reported by other investigators. In contrast, CLZ3 (Figure 25) represents a novel
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GSH adduct structure for this drug. For CLZ3, the [M-H]- ion with m/z of 548.099
is consistent with loss of the entire piperazine moiety, in addition to hydroxylation
and rearomatization following adduction with GSH. The peak labeled as a “d”
transition at m/z 275.005 corresponds to the neutral loss observed from the
cleavage of the sulfur of GSH from the rest of the tripeptide. The resulting
fragment represents the metabolized CLZ moiety still bound to the sulfur of GSH.
The “k” ion corresponds to a characteristic GSH fragment. Rearomatization of the
benzene ring is supported by the presence of the “k” peak and lack of an “i” peak,
suggesting that conjugation occurs at an aromatic site on the clozapine
metabolite.88
DZP1 is a previously unreported adduct for diazepam and was the only
one observed for this drug. The presence of the [M-H]- ion at m/z 606.154 is
consistent with a mechanism involving reduction of the diazepine ketone in the
parent drug to a hydroxyl group, hydroxylation of the 5-phenyl ring, and covalent
adduction of GSH with rearomatization of the phenyl group. The specific
fragment at m/z 588.142 is consistent with cleavage of a hydroxyl group, most
likely that attached to the 5-phenyl moiety. The specific fragment at m/z 315.044
may be derived via cleavage of both the 5-phenyl hydroxyl and the phenyl C-S
bond of the adduct. Rearomatization of the phenyl ring containing the site of
adduction is supported by the presence of the “k” fragment at m/z 272.098 in
addition to the lack of an “i” fragment. The remaining “b” and m/z 210.093 ions
are each consistent with GSH fragmentation.
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MDPV1 is identical in MS/MS characteristics to a previously reported GSH
adduct with this compound and which represents adduction to a demethylenated
diol metabolite.84 MDPV2 is the first of two previously unreported MDPV adducts
observed in this study. The [M-H]- ion at m/z 498.172 most likely represents
metabolic demethylenation, as with MDPV1, in addition to further metabolic loss
of the pyrrolidine ring via N-deamination, followed by covalent adduction by the
GSH thiol on the phenolic ring. The presence of a “d” fragment at m/z 225.060
further supports the identity of the adducted drug moiety, as it corresponds to the
mass of the moiety plus the sulfur of GSH. The presence of a “k” fragment with
m/z 272. 089 and lack of a detectable “i” fragment strongly indicates linkage of
the GSH sulfur to an aromatic carbon. The remaining “b” ion at m/z 143.046
represents a GSH fragment.
MDPV3 is a second unreported GSH adduct for this compound. Similar to
MDPV2, the [M-H]- ion at m/z 514.168 is consistent with demethylenation, loss of
the pyrrolidine ring, and covalent adduction of the GSH thiol. However, the
precursor ion mass for MDPV3 also indicates addition of a hydroxyl group, most
likely on the alkyl chain moiety. This interpretation is corroborated by the
presence of a “d” ion with m/z 241.068. Again, the presence of a “k” fragment at
m/z 272.103 along with the lack of an “i” fragment supports an aromatic thiol
linkage. The remaining “b” ion represents a GSH fragment, while the ion at m/z
378.808 is unidentified.
Two naltrexone-GSH adducts were observed in the present study and are
the first such derivatives reported in the literature. For NAL1, a [M-H]- ion at m/z
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645.249 is consistent with unmodified precursor drug directly adducted to GSH.
The MS/MS spectrum clearly shows the presence of “k” ions with lower
intensities of “i” and “d” ions (Figure 25). While not unequivocal, this pattern is
most consistent with thiol conjugation to the benzene ring in naltrexone. The “f”
and “b” ions represent GSH fragments.
The MS/MS spectrum for NAL2 exhibits an [M-H]- ion at m/z 663.260,
which is most consistent with GSH conjugation to a hydroxylated metabolite.
This interpretation is also supported by the presence of a “d” fragment at m/z
390.157 and a “j” fragment at m/z 358.184. The similar relative abundances of
the “k” and “i” ions along with the higher abundance of “d” as compared to “j” ions
suggest linkage of the thiol sulfur of GSH to an aliphatic carbon in the drug
moiety.88 While Figure 25 shows one possible structure consistent with these
data, the position of the hydroxyl group and C-S link cannot be unequivocally
determined without additional information.
GSH adducts with oxycodone have not previously been reported. In the
present study, OXY1 exhibited a [M-H]- ion at m/z 619.208, consistent with GSH
adduction to parent drug. The presence of an “i” fragment at m/z 306.077 at a
much higher abundance than the “k” ion at m/z 272.958, along with the absence
of a “d” ion, is strongly suggestive of a GSH thiol linkage to a benzylic carbon.
This determination of a benzylic linkage is in agreeance with the literature on
GSH adduct linkage sites.88 Based on these data, a possible structure for the
OXY1 adduct is shown in Figure 25. Evidence for a second GSH-oxycodone
adduct (OXY2) was also obtained. The [M-H]- ion at m/z 633.223 is 14 Da larger
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than the OXY1 species, suggesting GSH adduction to a metabolite of the drug.
As with OXY1, the presence of a high abundance “i” fragment at m/z 306.077
combined with the lack of a “d” ion is strongly suggestive of a GSH thiol linkage
to a benzylic carbon. However, without additional data, a putative structure for
this adduct is not proposed.
GSH adducts of 9-tetrahydrocannabinol (THC) have not previously been
reported in the literature. The present study identified four species consistent
with covalent adduction of GSH with THC, all proposed to result from
modification of THC metabolites oxidized at the 11 position or on the pentyl chain
of the parent drug. THC1 exhibited a [M-H]- ion at m/z 634.306, consistent with
GSH adduction to 11-hydroxy-Δ9-THC, a prominent metabolite of this
cannabinoid.88 The presence of a major “d” ion at m/z 361.205 in addition to the
“i” fragment further supports this interpretation. The data most support a benzylic
C-S linkage between the drug moiety and GSH, based on the substantially higher
intensity of the “i” fragment as compared to that of the “k” ion (Figure 25).
However, due to the presence of a definite “d” fragment, an aliphatic linkage
cannot be entirely ruled out.
The THC2 moiety exhibited a [M-H]- ion at m/z 650.301, which is
consistent with conjugation of GSH with another common THC metabolite, i.e.,
11-nor-9-carboxy-Δ9-THC. This interpretation is also supported by the presence
of a “d” fragment at m/z 377.199. The covalent linkage between the drug moiety
and the GSH sulfur is most likely aliphatic, since the intensity of the “k” ion (at
m/z 272.106) is higher than that of the “i” fragment at m/z 306.094.
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The structures of the detected adducts represented by THC3 and THC4
are more speculative, as they appear to involve adduction of secondary oxidized
THC metabolites. For example, THC3 exhibited a [M-H]- ion at m/z 666.297,
which would be consistent with GSH adduction to a hydroxylated metabolite of
11-nor-9-carboxy-Δ9-THC, a conclusion further supported by the presence of the
drug-specific “d” fragment at m/z 393.195. The lack of prominent “i” ions in the
spectrum suggests linkage of aromatic carbon to the GSH sulfur. The MS/MS
spectrum of THC4 exhibited a [M-H]- ion at m/z 678.334, i.e., 38 Da higher than
observed for THC2. This observation would be consistent with GSH adduction to
a metabolite of 11-nor-9-carboxy-Δ9-THC containing a second carboxyl function.
Furthermore, the appearance of “i” ions at much higher intensity than “k” ions, in
addition to the absence of “d” ions in this spectrum, suggests a linkage of the
GSH sulfur to a benzylic carbon. Nevertheless, additional data are required to
identify the exact nature of the metabolic modifications present in the THC3 and
THC4 adducts and the location of the C-S linkage in each species.
4.2.4 Task 2 Discussion
This task explored the capability of selected drugs of abuse to form adducts
with the tripeptide glutathione. The formed adducts result from covalent bonds
between the nucleophilic sulfur in GSH and an electrophilic site on the parent
drug or a metabolite. The formation of GSH-based adducts with drugs of abuse
has only been sparingly reported in the literature, with available data limited to
cocaine61, MDMA and MDPV84, and morphine58. In these examples, MDMA was
the only compound with reported GSH adducts formed by both the precursor
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drug and a metabolite. While previous work with these drugs has demonstrated
the capability to form adducts with GSH, there is clearly a lack of available
information on this phenomenon for other widely abused substances.
Of the 22 GSH adducts observed in this study, nine have been previously
reported in the literature (see Table 9 for references). The structures reported
previously all have masses which match closely with those observed in spectra
collected in the present study.58,61,80,81,84 A direct comparison of our spectral data
with previous reports is possible for MDMA and MDPV, where negative mode MS
ionization and analysis was also utilized. MS/MS data for fragments of GSH and
GSH containing compounds and molecular ion exact masses observed for
MDMA1, MDMA2, MDMA3, and MDPV1 in the present study agree with the data
previously reported with negative mode analysis.84
Plausible structures are proposed for the majority of the previously
unreported adducts identified in the present study, based upon HRMS accurate
mass, MS/MS data, and likely metabolic transformations. However, for the
OXY2, THC3, and THC4 adducts, the available data were insufficient to propose
a structure with a high degree of confidence. The fragmentation patterns
suggest that both OXY2 and THC4 have benzylic covalent thiol linkages, while
THC3 likely contains an aromatic linkage. The molecular ion masses of THC3
and THC4 seem to suggest further metabolic modifications to the metabolite 11nor-9-carboxy-Δ9-THC prior to covalent adduction with GSH, such as a
hydroxylation or further carboxylation. OXY2 also appears to have undergone
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additional metabolic modification prior to adduction, although the exact steps are
unclear.
While NAL1 and OXY1 have an adduct mass which corresponds to the parent
drug directly bound to GSH without any other modifications, the other structures
proposed for GSH adducts in Table 9 represent adducts formed by one or more
primary metabolites of the drug. One of the initial metabolic steps is likely to be
hydroxylation, as is consistent with the proposed structures for CLZ1, DZP1,
MDPV3, and NAL2. Hydroxylations are common oxidative steps in the metabolic
pathways of CLZ, DZP, and MDPV, although this pathway has not been reported
for NAL.129,133,134
Structures consistent with bond cleavage within the drug moiety were also
observed for three of the adducts. CLZ3 is proposed to have lost the piperazine
ring in addition to undergoing hydroxylation and rearomatization. While this
particular metabolite has not previously been reported in the literature, there
have been observations of modifications to the piperazine ring in CLZ, indicating
that it may be a site of potential metabolic processes resulting in loss of
piperazine ring.135 Loss of a piperazine ring has been exhibited in the
metabolism of other heterocycle containing compounds such as aildenafil.136
Formation of MDPV2 is associated with loss of the methylene bridge and
pyrrolidine moiety (via oxidative deamination) in addition to rearomatization, while
MDPV3 may form via the same process in addition to a hydroxylation on the
resultant alkyl chain. Demethylenation, common to either the orthocatechol or
orthoquinone, and oxidative deamination of methylenedioxy type drugs has been
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reported in the literature.84,134 The orthoquinone formed by some methylenedioxy
drugs has been reported to be the reactive metabolite responsible for toxicity.87
As mentioned previously, some of the drugs underwent a rearomatization step
following GSH adduction and NIH shift (CLZ1, MDPV1, MDPV2, NAL1, OXY1,
THC1, and THC2) while others did not (DZP1 and NAL2). This observation is
similar to what has been generally reported in the literature involving NIH shifts 19.
GSH adducts with ∆9-THC have not been previously reported. The proposed
structures for THC1 and THC2 are consistent with adducts formed from the
stable metabolites 11-OH-∆9-THC and 11-nor-9-carboxy-∆9-THC, respectively,
with direct binding to GSH. The fragmentation patterns and peak ratios
discussed in the Results section indicate the thiol linkages appear to be benzylic
for THC1 and aliphatic for THC2. The fact that these adducts are consistent with
the stable metabolites implies that there may be a reactive intermediate formed,
allowing for electrophilic interactions with the thiol moiety from GSH.
For the MS analysis of the GSH compounds in the present study, negative
mode scanning was utilized. This was chosen primarily to facilitate analysis of
adducted GSH fragmentation. GSH fragmentation patterns in negative mode are
well-established in the literature, and in fact have been studied for a variety of
covalent adducts, including those with aromatic, aliphatic, and benzylic
linkages.88,110 The observed transitions also provided more prominent and
clearer ion signals than those following initial analyses utilizing positive mode
scanning. Additionally, many of the parent drugs included here do not produce
prominent molecular ions or fragment ions in negative mode, thus minimizing
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potential interferences due to coelution with unreacted drug present in the assay
mixture at significantly higher concentrations than the formed adducts. While
positive mode analysis of the novel GSH adducts could provide additional data
for structural confirmation, preliminary use of positive mode for several of the
drugs in the present study did not provide useful fragmentation data. As other
authors have reported, positive mode ionization is not always helpful for
characterization of GSH adducts, particularly with certain drugs where doubly
charged [M+2H]+ ions are formed, as these do not allow for the neutral loss
analysis which is generally utilized in positive mode GSH studies.110 Although
negative ionization mode alone did not provide the data necessary for complete
structural analysis of all adducts, this approach did provide sufficient information
to determine a plausible adduct structure for most of the drugs under study.
Unequivocal structural confirmation, including identification of regioselectivity of
adduct formation where present, will require additional work with synthetic
standards and further analysis by HRMS and definitive techniques such as NMR.
4.3 Confirmation of adduction in human Hb by drugs of interest
4.3.1 Protein Adduction Assay Optimization
Optimization of the in vitro assay system for protein adduction required
numerous alterations from the previous assay used for GSH. Incubation time was
increased to six hours to provide more time for interactions between the
hemoglobin and the reactive metabolites. Several initial experiments utilized
various products containing a dialysis membrane layer as an attempt to separate
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the hemoglobin from the metabolic system. The use of dialysis membrane
microfuge inserts required significant scale up (approximately x10), and were
deemed non cost-effective. Dialysis membrane layers were then abandoned in
favor of ultra-fast centrifugation to pellet the HLM while the hemoglobin remained
suspended in the solution. Concentrations of IAM and trypsin were established
based on existing protocols in the literature regarding similar proteolytic
digestions.137
4.3.2 Analysis of Hemoglobin Trapping Assay Products
The full scan analysis of the tryptic digestion assay supernatant produced
a complex TIC (figure 28a). BioConfirm software was able to remove compounds
not relevant to the formed tryptic peptides to produce a total compound
chromatogram (TCC). The software then analyzed the TCC (Figure 28b) for
expected peptides, peptide fragments, and any modifications allowed for in the
sample processing method found in Figure 30 (full Bioconfirm method
parameters found in Figure 29). Each drug-related adduct modification was
manually input into the BioConfirm method based upon the observed masses
from the GSH and synthetic peptide studies. Once completed, BioConfirm output
a list of biomolecules found in the data. The MS data analyzed with BioConfirm
produced positive results for the adduction of APAP, for the first time confirming
via MS data what had been reported previously in the literature using
radiolabeling and HPLC studies.125,138 In fact, APAP adduction was observed for
both Hb β93Cys and the less reactive Hb β112Cys. Adduction was also observed
via MS data for α-PVP, METH, NAL, OXY, and THC, producing a total of 11
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potential adducts. A summary of all of the BioConfirm data for all of these
adducts can be found in Table 10. The mass difference, presented in ppm units,
falls within an acceptable range for all but three of the 11 adducts observed in the
MS studies. Generally, a TOF is capable of <5 ppm measurments139; only
adducts 6, 9, and 11 fell outside of this range. Five of the potential adducts were
also reported by BioConfirm to contain more than one modification on the
analyzed peptide (i.e. an additional hydroxylation and/or acetylation). These
additional modifications lower the certainty of the presence of adducts 5, 6, 9, 10,
and 11, but was not enough to eliminate these as potential adducts.

Figure 28. TIC (a) and TCC (b) for the APAP+Hb adduct. The removal of certain peaks was
accomplished using the BioConfirm software.
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Parameter

Value

Extraction algorithm

Small Molecules

Restrict m/z to

350-2000

Use peaks with height

100 counts

Positive ions

+H, +Na, +K, +NH4

Neutral losses

H2O

Isotope model

Peptides

Mass filters

none

Maximum number of peaks

50 largest

Figure 29. BioConfirm method parameters.

Figure 30. The BioConfirm sample processing method utilized for the adducted tryptic
peptides. Modifications and profiles included the modifications for acetylation,
hydroxylation, and the adducted drug moieties observed in the GSH experiments or
synthetic peptide experiments performed by Dr. Carolina Moller (publication pending).
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Adduction
Adduct

Adducted Peptide
Other Mods

Δm/z (ppm)

Site

Mass

1

APAP1

Hb β93

none

2.93

1569.718

2

APAP1

Hb β112

none

-3.29

1868.0069

3

α-PVP1

Hb β93

none

-3.63

1651.822

4

METH1

Hb β93

none

-4.63

1597.7632

5

METH1

Hb α104

1Hydrox.+1Acetyl.

3.36

3171.7261

6

METH1

Hb β93

1Acetyl.

5.14

1609.7728

7

NAL1

Hb β93

none

-0.61

1759.8117

8

OXY1

Hb β93

none

3.57

1733.8033

9

OXY1

Hb α104

1Hydrox.+1Acetyl.

7.84

3337.7682

10

THC1

Hb β93

1Hydrox.+1Acetyl.

4.34

2914.4338*

11

THC2

Hb β93

1Hydrox.

-7.16

1780.8466

Table 10. Summary of MS data collected for Hb adducts. The asterisk for adduct 11
indicates a missed tryptic cleavage in the identified adduct.

4.3.3 MS/MS Analysis of Hemoglobin Adducts
Each drug which produced a potential adduct was additionally subjected
to MS/MS analysis using the Auto MS/MS scan mode data. BioConfirm
successfully identified MS/MS fragmentation for two of the adducts from Table
10, APAP1 modified Hb β93 and α-PVP1 modified Hb β93. While BioConfirm is
capable of labeling individual amino acids and both b and y fragments in
accordance with the a,b,c and x,y,z nomenclature, it fails to label any other peaks
which may be pertinent. Therefore, each spectrum was manually compared to a
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list of theoretical peaks provided by the MS-Product program of Protein
Prospector (http://prospector.ucsf.edu). Protein Prospector is an online series of
tools used for proteomic data mining specifically with mass spectrometry. The
programs were developed by the University of California at San Francisco Mass
Spectrometry Facility. The parameters used to compile the theoretical peak table
can be found in Table 11.
Parameter

Value

Sequence

Based on hypothesized match done by BioConifrm
software
Modification represented by cysteine residue followed by
parentheses containing the exact mass of the modification

N-term Sequence

a, b, c

C-term Sequence

x, y, z

Internal Fragment

Allow for internal fragmentation

Neutral-loss

-H2O (S, T, E, D)

Sequence

-NH3 (R, K, Q, N)

Peeling

B+H2O (R, H, K)

Sequence
Max Charge

2

Mass Type

Monoisotopic

Instrument

ESI-Q-TOF

Table 11. Protein Prospector parameters
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In the BioConfirm data for the APAP adduct with Hb, 11 peaks were
identified in the MS/MS spectrum (Figure 31). Using the potential peak list
populated by Protein Prospector, 18 additional peaks were identified. The
resulting 29 peaks along with the corresponding fragment can be found in Table
12. The MS/MS data of the negative control unmodified peptide chain can be
found in Figure 32.

Figure 31. MS/MS identification of the adduct formed between APAPand Hb β93. (A)
BioConfirm labeled MS/MS spectrum 11 peaks in the spectrum with the b fragment in blue,
the y fragments in red, and the amino acid histidine shown in green. (B) Putative structure
of APAP adduct. (C) Peptide fragmentation diagram for MS/MS data.
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Fragment Mass

Fragment

Fragment Mass

Fragment

110.0713

H

593.3293*

TFATLS-28

120.0808

F

633.2573

y4-H2O

145.0972

AT-28

651.2678

y4

147.1128

y1

729.2784

ELHC(+149.06)D-H2O

217.0819

SE

747.3254

y5-NH3

257.6081+2*

y3+2

764.3519

y5

288.1343

b3-H2O

785.8701+2

MH+2

359.1714

b4-H2O

835.456

TFATLSEL-28

433.2445

FATL

876.368

y6-NH3

439.23

SELH-28

980.4265

y7

460.2191

b5-H2O

982.4993

TFATLSELH-H2O

467.2249

SELH

1093.5106

y8

478.2296

b5

1194.5583

y9

496.1984

y3-H2O

1265.5954

y10

514.2089

y3

Table 12. Summary of MS/MS peak information for Hb+APAP adduct. Possible match
peaks are indicated with an asterisk.

In the BioConfirm data for the α-PVP adduct with Hb, 3 peaks were
identified in the MS/MS spectrum (Figure 33). Using the potential peak list
populated by Protein Prospector, 7 additional peaks were identified. The resulting
10 peaks along with the corresponding fragment can be found in Table 13.
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Figure 32. MS/MS data for the unmodified peptide containing the Hb β93 cysteine.

Figure 33. MS/MS identification of the adduct formed between α-PVP and Hb β93. (A)
BioConfirm labeled MS/MS spectrum with 3 peaks identified in the spectrum, all y
fragments shown in red. (B) Putative structure of α-PVP adduct. (C) Peptide fragmentation
diagram for MS/MS data.
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Fragment Mass

Fragment

129.1022

K

130.0863

y1-NH3

147.1128

y1

278.1499

a3

373.2082

ATLS

562.2984

LSELH-H2O

563.3188*

a6

818.4068+2

MH-NH3+2

826.9201+2

MH+2

846.4519

y5

Table 13. Summary of MS/MS peak information for Hb+α-PVP adduct. Possible match
peaks are indicated with an asterisk.

4.3.4 Task 3 Discussion
Task 3 examined the capability of drugs of abuse to form covalent adducts
with hemoglobin in vitro. As discussed in section 2.4.1, adducts formed between
drugs of abuse and proteins is not a new concept, but the literature is limited.
Few examples exist of studies analyzing these adducts, with the exceptions
being ethanol, morphine, and cocaine.52,53,59,65 Acetaminophen has also been
shown via HPLC analysis to bind directly to hemoglobin.138 However, there has
not been any mass spectrometric investigation into these formed adducts. Table
10 exhibits information supporting the formation of adducts formed between
hemoglobin and six drugs of interest in this study; APAP, α-PVP, METH, NAL,
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OXY, and THC. The use of HRMS analysis increased the confidence in these
data, despite the uncertainty regarding the adducts with Δm/z ≥5 ppm.
Additionally, the adducts listed as having more than one modification introduce
another degree of uncertainty, but were still included as the BioConfirm software
identified them. Each modification for a drug of abuse adduct had to be manually
generated. An example of a manual modification setup for BioConfirm can be
seen in Figure 34.

Figure 34. Example of custom modification settings used for BioConfirm analysis

An important note regarding all of the observed adducts is that they are
drug specific. Rather than a portion of a drug being covalently bound, such as a
phenyl ring or amine, the entire drug moiety is bound to the cysteine of Hb. This
implies that any long-term biomarkers arising from the use of protein adducts will
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be indicative of a specific drug, rather than a class of drugs. It also implies that
the use of protein adducts as biomarkers could be used in confirmatory tests,
rather than screening. There may also be more adducts formed than what was
detected by the QTOF instrument, including those formed with different drugs of
interest. The formed adducts are often produced at very low concentrations, and
it is possible that the instrument, based upon user parameters, disregarded
adduct peaks in favor of fragments with significantly higher concentration.
The MS/MS data provide further evidence of the covalent adduction by
APAP and α-PVP. Both of these drugs were covalently bound to Hb β93, rather
than the other two possible cysteines. This is unsurprising since Hb β93 is the
most reactive cysteine residue found in Hb99, as it lies largely exposed on the
surface of the protein (Figure 35).
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Figure 35. Space-filled model of Hb with Hb β93 highlighted in green.

Figure 36. Space-filled model of Hb with His and Lys residues highlighted in green.

MS/MS data were unable to be collected for nine of the eleven adducts
observed in the MS analysis. This could be the result of low concentrations of the
formed adducts. As mentioned earlier in this section, the adducts are present in
much lower concentrations than the other components of the assay analyzed by
the instrument. Parameters of the QTOF analytical method may have
accidentally excluded some of the adducts. To be certain, exclusion lists would
need to be created containing the masses of the non-adducted peptides and any
other irrelevant molecules.
While Hb β93 is the most reactive cysteine, it is possible that other adducts
are formed with additional nucleophilic amino acid residues on the hemoglobin
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molecule. As visible in Figure 36, there are many other nucleophilic sites in the
hemoglobin protein. These include the amino acids histidine and lysine, both of
which have been shown to form covalent adducts with electrophiles.73 Any of
these adducts would have been missed since cysteine was specifically targeted
in the BioConfirm parameters allowed for modifications (see Figure 34). Further
work would therefore be required to determine any additional sites of possible
adduction by the drugs of interest.
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5. Summary and Prospect
The goal of this research was to investigate the potential of adduct
formation between selected drugs of abuse and the blood protein hemoglobin.
This was accomplished through a series of steps, including the determination of
fragmentation of the parent drugs and the analysis of adduction with the small
tripeptide glutathione. This work successfully compiled a list of common
fragments for all 16 of the drugs of interest, which, although not thoroughly
utilized for this work, may provide insight in the future to potential fragmentation
by adducted drug moieties. This work also identified and characterized 22
adducts with GSH, 12 of which were novel. Although structural determination
was not a focus of this research, plausible structures for 9 of the 12 novel
adducts were proposed. Positive ionization analysis of the GSH adducts may
provide more details into the missing structures and aid in confirming the
proposed structures of the putative adducts. Lastly, this research was able to
successfully collect HRMS data for eleven Hb adducts with the drugs of interest
and MS/MS data for two adducts, thus confirming the adduction by α-PVP and
APAP.
This research has laid the groundwork for future expansion into the topic
of covalent protein adduction by drugs of abuse. One major area of potential
future work is the investigation of other proteins, specifically human serum
albumin (HSA). HSA, like Hb, is a common blood protein with a free cysteine
residue at Cys34. HSA is also produced in the liver, where much of the
metabolism in the body takes place. This could potentially drive the adduction of
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short-lived reactive metabolites with HSA. There is also a plethora of literature
regarding the adduction of compounds to HSA. The metabolically generated
carcinogen (±)-r-7,t-8-dihydroxy-c-9,c-10-epoxy-7,8,9,10-tetrahydrobenze (antiBaPDE) has been shown via fluorescence line narrowing spectroscopy to
produce multiple adducts with HSA.140 Adducts have also been observed
between HSA and atrazine, a common herbicide.141 Finally, the structurally
similar bovine serum albumin (BSA) has been shown to form adducts with
APAP.123 HSA, much like Hb, is not limited to cysteine as possible sites of
adduction, as studies have shown the nucleophilic properties of multiple histidine
and lysine residues promote adduction.73
The concentration of many protein adducts has been shown to be very
low, with in vitro studies reporting that a majority of analyzed compounds
exhibited protein binding with less than 10% of the overall metabolome.142
APAP, a drug observed in the present study to have the highest adduct
concentrations, was observed modifying proteins with 3.1% of the overall
metabolome.142 In vivo studies have shown even lower concentrations present,
with Rubino et al. reporting that hemoglobin modified by a mass 200 Daltons or
higher was present at concentrations of 1ppb or lower.143 A solution to this
limitation would be to carry out an enrichment procedure by isolating the modified
protein before analysis.
This work has many implications in the field of forensics. At the present
time, hair analysis is the only available method for long-term detection of illicit
drug use. However, hair analysis suffers from methodological and interpretive
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challenges, and the mechanisms by which most drugs incorporate into hair are
not clearly established.21 Additionally, current blood and urine biomarkers are
removed from the body after just a few days, restricting the window of detection
for many drugs of abuse. The use of protein adducts as long-term biomarkers of
exposure may be used to supplement existing analytical methods to ensure
complete detection of drugs of abuse. As all of the thusly identified proteins
adducts are specific to individual drugs, it may be possible to confirm not only the
class of drugs consumed but also the exact drug consumed based upon the
MS/MS data collected for an individual’s sample. This specificity combined with
the overall stability makes long-term biomarkers of exposure a favorable and
effective application of protein adducts formed by drugs of abuse.
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